Àô¹Ò«æ¯g

°ª°¶®p, §õ«Ø½å

¥x¥_ºa¥ÁÁ`Âå°|«æ¶E³¡¡B¶§©ú¤j¾Ç«æ¶EÂå¾Ç¬ì

¡@

©Ò¿×Àô¹Ò«æ¯g¡A¬O«ü¦]Àô¹Ò¤¤ªº¥Íª«¡Bª«²z¡B¤Æ¾Çµ¥¦]¤l¡A©Ò³y¦¨ªº«æ©Ê¯e¯f©Î¶Ë®`¡A¥]¬A°ª¤s¡B­¸¯è¡B§N¼ö¦³Ãö«æ¯g¡B»P¤ô¦³Ãö«æ¯g¡B¨`¶Ë¡B¿ç®g¤Î¦MÀIª««~©M¬rª««æ¯gµ¥¡C¨`¶Ë¡B¿ç®g¤Î¦MÀIª««~©M¬rª«µ¥«æ¯g¡A¥t³¹¤w¦³°Q½×¡A¥»³¹¤£¦AÂØ­z¡C

¡@

°ª¤s¤Î­¸¯è«æ¯g

»OÆW¦³¦Ê¤À¤§¤»¤Q¥|ªº¤g¦a¬O¤s¦a¡A°ª¤sªº´º¦â¦p¸Ö¦pµe¡A°êµe¤¤ªº¬ü´º¸g±`¥i¦b¤s¤¤¯B²{¡Aªñ¦~¨Ó»OÆWªº®È¹C­·®ðº¥º¥²±¦æ¡A³\¦hªº®È¹C¾ÚÂI³£¦³¤H¦h¡B¶ë¨®©Îż¶Ãªº²{¶H¡A¦Ó°ª¤s¤£¶È¦³¨ä¿W¯Sªº¬ü´º¡A¦Ó¨ä²M·s¡B¥¼¨ü¦Ã¬V¡B»·Â÷¹Ð¾]¡B»·Â÷¤H¸s¡B¨É¨ü¤j¦ÛµMªº¯S½è¡A§ó¬°³\¦h¥­¤é¦b³o¤u°Ó·~ªÀ·|¦£¸Lªº¤H­Ì©Ò³ß·R¡C¦]¦¹ªñ¦~¨Ó»OÆWªºµn¤s¹B°Ê½´«kµo®i¡Aµn¤s¤H¤f¤£Â_¼W¥[¡CµM¨C¦~Á`¦³¤@¨Ç¤sÃøµo¥Í¡A³y¦¨³\¦h¿ò¾Ñ(ÁöµM¤sÃø·N¥~µo¥Íªº¤ñ²v¡A»·§C©ó¤@¯ë¨Æ¬G¦p·Ä¤ô¡B¨®º×µ¥ªºµo¥Í¤ñ²v¡AµM¥Ñ©ó¨ä·s»D©Ê¸û°ª¡A¬G±`Åý¤j®a»~»{¬°¤sÃø«Ü®e·N©ö´N·|µo¥Í1)¡CÁöµM¤sÃø¤´¬O¥HåP¸¨¤Î¥¢·Å¬°³Ì¦h2¡A¦ý¨ä¤¤³\¦h·N¥~«o¤´»P°ª¤s¯g¦³Ãö¡C¦b¥xÆW¡A¤]¦P¼Ë¦³ÄY­«°ª¤sªÍ¤ô¸~¤Î°ª¤s¸£¤ô¸~ªº³ø§i¡C3

µM¦Ó°ª¤s¯g«o¤£¥u¬O®{¨Bµn¤sªÌªº±M§Q¡A°£¤Fµn¤s¤§¥~¡A¥Ñ©ó­¸¾÷¡B¨T¨®®È¹Cªº¤è«K¡A³\¦h¤H¦b¤£¸g·Nªºª¬ªp¤U¡A§Y¤w§Ö³tµn¤W¨¬¥H²£¥Í°ª¤s¯gªº°ª¤s¡A½Ñ¦p§¤­¸¾÷¨ì¦èÂ꺩ÔÂÄ¡A±u«â¦b¯E¿«ªº«C±dÂðª­ì¡A­¼Æl¨®¤W¼Ú¬wªºªüº¸¨õ´µ¤s¡A¶}¨®¤W¥xÆWªº¦XÅw¤s¡A¥H¤Î¥@¬É¤W³\¦h·Æ³·³Ó¦a¡A¦p¬ü°êªº¸¨ÁF¤s°Ïµ¥¡A¬Ò¤w¨ì¹F·|²£¥Í°ª¤s¯gªº°ª«×¡C4®Ú¾Ú³ø§iÅã¥Ü¡A³¥¥~ªº«D³Ð¶Ë«æ¯g¤¤¡A°£¤F·P«_¤Î¸¡Âm¥~¡A´N¥H°ª¤s¯g¬°³Ì¦h¡A¨ä­«­n©Ê¥i¨£¤@¯ë¡C®Ú¾Ú¬ü°êªº³ø§i¡A¦b¬ìù©Ô¦h¦{¡A¤G¤d¤@¦Ê¤½¤Ø°ªªº·|ij¤¤¤ß¶}·|ªºÂå¥Í¡A¨ä¤¤¬ù25%¡A²£¥Íµ{«×¤£µ¥ªº«æ©Ê°ª¤s¯f¯gª¬¡C5¦Ó¦b¨ä¥L¤¶©ó2,200-2,700¤½¤Ø°ªªº´ç°²³Ó¦a¡A«æ©Ê°ª¤s¯fªºµo¥Í²v«h¬ù¦b17-40%¤§¶¡¡C¦p§¤­¸¾÷§Ö³tµn¤W2,800¤½¤Øªº°ª¤s¡A«h°ª¹F49%ªº¤H·|²£¥Í°ª¤s¯g¡C6

°ª¤sÀô¹Òªº§ïÅÜ

ÀHµÛ°ª«×ªº¼W¥[¡A¤j®ðÀ£¤O³vº¥ªº­°§C¡A§l¤J®ñ®ðªº¤ÀÀ£¤]ÀHµÛ­°§C(ªí¤@)¡C2¦b5,500¤½¤Øªº°ª«×¡A¤j®ðÀ£¤O¤j¬ù¥u¦³®ü¥­­±ªº¤@¥b¡F¦b®J¥±°Ç´µ®p(8848¤½¤Ø)ªº°ª«×¡A¤j®ðÀ£¤O«h¬ù¥u³Ñ¤U®ü¥­­±ªº¤T¤À¤§¤@¡C¦¹¥~½n«×¡B©u¸`¤Î¤é©]§ïÅÜ¡A¤]·|¼vÅT¤j®ðÀ£¤O¡A¦p¦b¦P¼Ëªº°ª«×¤U¡A¶V»·Â÷¨ª¹D¡A¤j®ðÀ£¤O±N·|¶V§C¡A¦]¦¹®ñ®ð¤ÀÀ£¤]·|Åܱo§ó§C¡F¥V¤Ñªº¤j®ðÀ£¤O¡A·|¤ñ®L¤Ñ§C¡F±ß¤Wªº¤j®ðÀ£¤O¡A¤S¤ñ¥Õ¤Ñ§C¡A±ß¤Wªº§CÀ£¨¦©³¥i¤ñ¥Õ¤Ñ§C10²@¦Ì¨E¬W¡A§Y¬Û·í©ó¥Í²z¤W¤É°ª¤F200¤½¤Øªº°ª«×¡A¦]¦¹¦b±ß¤W°ª¤s¯g·|±`Åܱo§óÄY­«¡C2

ÀHµÛ°ª«×ªº¼W¥[¡A®ð·Å·|³vº¥­°§C¡A¥­§¡¨C¤W¤É¤@¤d¤½¤Ø¡A®ð·Å·|¤U­°6.5¢J¡A¥Ñ©ó´H§N»P¯Ê®ñªº¥[¦¨¼vÅT¡A·|¨Ï±o§C·Åªº¶Ë®`¤Î°ª¤s¯gÅܱo§óÄY­«¡C2

¥Ñ©ó¦Ç¹Ð¡B¶³¥H¤Î¤ô»]¨Tªº´î¤Ö¡Aµµ¥~¥úÀHµÛ°ª«×ªº¼W¥[¡A¦Ó¬ï³z¼W¥[¡C¤j¬ù¨C¤É°ª¤T¦Ê¤½¤Ø¡Aµµ¥~¥ú¬ï³z¼W¥[4%¡C2¦]¦¹µo¥ÍÅζˡB¥Ö½§Àù¤Î³·ª¼ªº¾÷·|¤]¸û°ª¡C

¡@

ªí¤@¡B¤£¦P°ª«×¤U®ðÅé¤ÀÀ£(³æ¦ì¬°²@¦Ì¨E¬W)

¤½¤Ø

­^§`

¤j®ðÀ£¤O

PiO2

PaO2

PaCO2

SaO2(%)

0

0

760

149

94

41

97

1,500

5,000

630

122

66

39

92

2,400

8,000

564

108

60

37

89

3,000

10,000

523

100

53

36

85

3,700

12,000

483

91

52

35

83

4,600

15,000

412

76

44

32

75

5,500

18,000

379

69

40

29

71

6,100

20,000

349

63

38

21

65

7,300

24,000

280

52

34

16

50

8,500

28,000

250

42

28*

7*

30*

9,100

30,000

226

37

-

-

-

*¦ô­p­È

¡@

¤HÅé¹ï°ª«×ªº¾AÀ³

¦p¤H­Ì§Ö³t¤W¤É¦Ü®J¥±°Ç´µ®p(8848¤½¤Ø)ªº°ª«×¡A±N¦b´X¤ÀÄÁ¤º§Y³à¥¢·NÃÑ¡AµM«á«Ü§Ö´N·|¦º¤`¡CµM¦Ó¡A¦pµn¤sªÌ¸g¹L¼Æ¶gªº¾AÀ³«á¡A«h¦³¤H¥i¦b¤£Äâ±a®ñ®ðªºª¬ªp¤U¡Aµn¤W®J¥±°Ç´µ®p¡A¦Ó¶È²£¥Í«Ü»´·Lªº¯gª¬¡CÃÒ©ú¤HÃþ½T¹ê¨ã¦³°ª«×ªº¾AÀ³¯à¤O¡C2,7

¬°¤F¨Ï¨­Åé²Ó­M¡A¯à¦b¯Ê®ñªº°ª¤s¡Aºû«ù¥¿±`ªº¥\¯à¡A¨­Åé±N²£¥Í³\¦hªº§ïÅÜ¡A¼W¥[²Ó­M¹ï®ñ®ðªºÀò±o¤Î§Q¥Î¡A¨Ó¾AÀ³°ª¤s§CÀ£¯Ê®ñªºÀô¹Ò¡C¦Ó³o¨Ç¾AÀ³³q±`¦b¤U¤s®É¡AÀHµÛ°ª«×ªº­°§C¡A¤]±N³vº¥®ø¥¢¡C¦Ó¹ï°ª«×¾AÀ³¦¨¥\»P§_¡A«h¨ú¨M©ó¯Ê®ñªºÄY­«µ{«×¡B¯Ê®ñµo¥Íªº³t«×¥H¤Î­Ó¤Hªº¨­Å骬ªp¡C¦³¨Ç¤H¦b¨S¦³¯gª¬ªºª¬ªp¤U¡A´N¯à§Ö³tªº¾AÀ³¡F¦³¤H«h¦b²£¥Í«æ©Ê°ª¤s¯f«á¡Aº¥º¥«ì´_¦Ó¾AÀ³¡FµM¦Ó¥t¥~¤@¨Ç¤HÁö¸g¹L¼Æ¶gªº´Á¶¡¡A«o¤´µLªk¾AÀ³°ª«×ªºÃnÅS¡C2

¡@

°ª¤s¯g(high altitude syndrome)

°ª¤s¯g¡A¥i»¡¬O¦b§CÀ£¯Ê®ñªº°ª¤sÀô¹ÒùØ¡A©Ò²£¥Íªº¯fª¬¡A¥¦¥]¬A¤F«æ©Ê°ª¤s¯f¡B°ª¤sªÍ¤ô¸~¡B°ª¤s¸£¤ô¸~¡B°ª¤sµøºô½¤¯fÅܵ¥¦UºØ¦b¦¹Àô¹Ò¤¤©Ò²£¥Íªº¯fÅÜ¡CÁöµM³o¨Ç¯f¯gªº²£¥Í¡A±`¦³Ãþ¦üªº¯f²z²{¶H¡AµM¨ä½T¹êªº¾÷Âà¡A¤´¦³³\¦h©|¤£²M·¡¡C¨Ò¦p¡A¬°¦ó¦b¦P¼Ëªº¯Ê®ñÀô¹ÒùØ¡A¦³¨Ç¤H¯Ê®ñ¤ñ¸ûÄY­«¡A²£¥Í°ª¤s¯g¡A¦ý¦³¨Ç¤H«o¥i¥H¬Û¦wµL¨Æ¡C¦Ó°ª¤s¯gªºµo¥Í»P¯Ê®ñªºµo¥Í¡A®É¶¡¤W±`¦³¤@¬q¸¨®t¡A¦Ó¤£¬O¦P®Éµo¥Í¡C°Êª«¹êÅç¤]Åã¥Ü¡A¦bµ¹¤©¥¿±`®ñ®ð¤U¡A³vº¥´î§CÀ£¤O«á¦º¤`¡A¨ä©Ò²£¥Íªº¯gª¬¡A»P¦b¯Ê®ñ¤U¦º¤`ªº±¡§Î¡A«D±`¬Û¦ü¡C¦]¦¹Åã¥Ü¯Ê®ñ¥»¨­¡A¥i¯à¨Ã¤£¬O°ª¤s¯gªº°ß¤@­ì¦]¡C2,8

·í¤W¤Éªº³t«×¡A¶W¹L¾AÀ³ªº³t²v®É¡A°ª¤s¯g´N·|µo¥Í¡C¦Ó¦b·¥°ª®ü©Þ¡A¥Ñ©ó¶W¹L¤HÃþ¾AÀ³ªº·¥­­¡AÁö¸g¹L¾AÀ³¡A°ª¤s¯g¤´µM·|µo¥Í¡A¦]¦¹¤HÃþµLªkªø´Á©~¦í¦b³oºØÀô¹ÒùØ¡C2

·í¤H­Ì¬ðµM¼ÉÅS¦b·¥ºÝªº°ª«×®É¡A¦º¤`«Ü§Ö´N·|µo¥Í¡AµM¦Ó¦pªG¬OºCºC¦a¨ì¹F¦¹°ª«×¡A¥i¯à¥u·|²£¥Í»´·L«æ©Ê°ª¤s¯f¡C±q»´·Lªº¯Ê®ñ¡B«æ©Ê°ª¤s¯fªº²£¥Í¡A¨ì­««×ªº°ª¤sªÍ¤ô¸~¡B°ª¤s¸£¤ô¸~¡A¦³µÛ«D±`¬Û¦üªº¯f²z²{¶H¡A¦]¦¹¬Û¦Pªº¯gª¬¡A·|¦b¤£¦Pªº¶EÂ_¤¤¥X²{¡F¦Ó¦P¤@­Ó¯f¤H¤]¥i¦P®É¦X¨Ö³\¦h¤£¦Pªº¶EÂ_¡A¦p¦P®É¥X²{«æ©Ê°ª¤s¯f¡B°ª¤sªÍ¤ô¸~¤Î°ª¤s¸£¤ô¸~¡C³o¨Ç¤£¦P¶EÂ_ªº¬É­­¡A±`¤£©ú½T¡CµM¥¦­Ì³q±`³£µo¥Í©ó¤W¤Éªº¼Æ¤Ñ¤§¤º¡A¨Ã¥B¥i¦b¤U­°©Îµ¹®ñ®ð«á·|Àò±o§ïµ½¡C2

¦b1875¦~¡A­¼§¤Zethin¼ö®ð²y¡Aªá¤T­Ó¤p®Éªº®É¶¡¡A§Ö³t¤W¤É¦Ü¤K¤d¤½¤Ø°ª«×¡AµM«á¦b¤@¤p®É¤º¡A§Ö³t¤U­°¦^¥­¦a¡A¨ä¤¤°ß¤@¥ÍÁÙªÌTissandier¡A´¿´y­z¨ä¤W¤Éªº¸g¹L¡y´X¥G¦b§ÚÁÙ¨S¦³·Q¨ìªº±¡§Î¤U¡A§Ú¤w¥¢¥h¬¡°Êªº¯à¤O¡A«Ü§Ö¦a¡A§Ú´NÅܱo§¹¥þ°Ê¼u¤£±o¡C±µªñ7,500¤½¤Ø°ª«×®É¡A§Ú¦³¤@ºØ©_¯Sªº³Â¤ì·Pı¡A¨­Åé¤Î¤ß´¼Åܱo¶V¨Ó¶V·L®z¡Aº¥º¥¦a¡A§Ú¥¢¥h¤Fª¾Ä±¡C§Ú´¿·Q§ì¦í®ñ®ðºÞ¡A¦ý¤â«oµLªk©ï°_¡AÁöµM¦¹®É§Úªº¤ßÆF¤´µM«D±`²M´·¡A§Ú¤@ª½¾®µøµÛÀ£¤O­p¡A«ü°w«Ü§Ö¨ì¹F280²@¦Ì¨E¬W¡A¥H«á§Ú´N¤°»ò¤]¤£ª¾¹D¤F¡C§Ú´¿·Q§o³Û¡A»¡§Ú­Ì¤w¨ì¹F8,000¤½¤Ø°ª«×¡A¦ý¦¹®É§Úªº¦ÞÀY¤w³Â¤ì¡A§Úªº²´·ú«Ü§Ö¦a³¬¤W¡AµM«á¥¢¥h¤Fª¾Ä±----·í®ð²y§Ö³t¤U­°®É¡A§Úªº¯gª¬«Ü§Ö´N®ø¥¢¡C¡z2

Tissandierªº¸g¾ú¡A­Y¤Î®Éµ¹¤©®ñ®ð¡AÀ³¥i¨¾¤î©Î¥ß§Y§ïµ½¨ä¯gª¬¡C·í«æ©Ê¯Ê®ñ¡APaO2§C©ó30²@¦Ì¨E¬W¡A©Î°Ê¯ß¦å®ñ¹¡©M«×¦b40-60%®É¡A·NÃѫܧִN·|³à¥¢¡C¦Ó³oºØ²{¶H¡A¥iÂǵۥߧYµ¹¤©®ñ®ð¡B§Ö³t¥[À£©Î¤U­°¡B©ÎÁB¥¿¼ç¦b­ì¦]¦p°±¤î¹L«×¹B°Êµ¥¡A¦Ó§Ö³t§ïµ½¡C¦¹¥~¡A±j­¢¦Û¤v¹L«×´«®ð¡A«h©µªø¦³®Ä·NÃѪº®É¶¡¡A¦b¤d¶v¤@¾v¤§»Ú¡A³o©Î³\¥i¥H®¾±Ï¤@¨Ç¥Í©R¡C2

«æ©Ê°ª¤s¯f¡iacute mountain sickness(AMS)¡j

«æ©Ê°ª¤s¯f¡A³q±`µo¥Í©ó¤W¤É¼Æ¤p®É¦Ü¼Æ¤Ñ¤º(¦h¼Æµo¥Í¦b24¤p®É¤º) 2,7,8¡A¨äµo¥Í²v¤ÎÄY­««×¡A¨ú¨M©ó¤W¤Éªº³t«×¡B¤W¤Éªº°ª«×(¤×¨ä¬OºÎ¯v®Éªº°ª«×)¡B¦b°ª®ü©Þ°±¯dªº®É¶¡¡B¤W¤É®ÉÅé¤O®ø¯Óªº¦h¹è¡B¥H¤Î­Ó¤Hªº¨­Å骬ªpµ¥¡C¤@¯ë¦Ó¨¥¡A¤W¤Éªº³t«×¶V§Ö¡B¤W¤Éªº°ª«×¶V°ª¡B¦b°ª®ü©Þ°±¯dªº®É¶¡¶Vªø¡B¤W¤É®ÉÅé¤O®ø¯Óªº¶V¦h¡B¥H¤Î­Ó¤Hªº¨­Å骬ªp¶V®t¡A¶V®e©öµo¥Í¡C¤k©Êµo¥ÍAMSªº¾÷·|µy·L¼W¥[¡A¦ýµo¥Í°ª¤sªÍ¤ô¸~ªº¾÷·|«h¸û§C¡C¦~ÄÖ¸û»´ªÌ¡A»P´¿¦³«æ©Ê°ª¤s¯f¯f¥vªÌ¡A³q±`µo¥Í«æ©Ê°ª¤s¯fªº¾÷·|¸û¤j¡C2

«æ©Ê°ª¤s¯fªºªì´Á¯gª¬¡A»P³Ü°s«á±J¾K(alcohol hangover)«D±`¬Û¦ü(¦pªí¤G)¡A¥]¬AÀYµh¡BÀY·w¡B¹½­¹¡B¥¢¯v¡Bäú¤ß¡B©PÃä¤ô¸~¤Î¥þ¨­­Â«åµ¥¡F¤¤«×ªº¯gª¬«h¥]¬A¹Ã¦R¡BµLªk½w¸ÑªºÀYµh¡B¥H¤Î§¿¶q´î¤Öµ¥¡FÄY­«ªº¯gª¬«h¥]¬A·NÃѧïÅÜ¡B¨BºA¤£Ã­¡B¥ð®§®É©I§l§xÃø¡BªÍ³¡¥iÅ¥¨ìÅo­µ¡B¥H¤ÎµoÖæµ¥¡A³o¨Ç¯gª¬¹ê¤w¬O°ª¤sªÍ¤ô¸~¡B°ª¤s¸£¤ô¸~ªº¯gª¬¤F¡C2¤@¯ë¦Ó¨¥¡A¥u­n¯f±w¦³µn°ª¡A¥B°ª¤s¯f«ü¼Æ(AMS score)¤j©ó¤T¤À¡A§Y¥i¶EÂ_¬°«æ©Ê°ª¤s¯f¡C4

©PÃ䪺¤ô¸~¡A¦pÁy³¡¡B¤â³¡¤Î¸}½ï¤ô¸~¡A¤]¬O°ª¤s¯f±`µo¥Íªº¯gª¬¡C³q±`¤k©Êµo¥Í¾÷·|¸û°ª¡A¨ä­ì¦]¥i¯à¬O°ª¤s¤ô¥÷¶J¯d©Ò­P¡AªvÀø«h¬O¥H¤U¤s¤Î¨Ï¥Î§Q§¿¾¯¬°¥D¡C2,7

¦p°ª«×¤£Ä~Äò¤W¤É¡A»´«×ªº«æ©Ê°ª¤s¯f¡A³q±`¦b´X¤Ñ¤º·|§ïµ½¡CµMÄY­«ªº«æ©Ê°ª¤s¯f¡A³q±`¤w¥Nªí¬O°ª¤sªÍ¤ô¸~¡B°ª¤s¸£¤ô¸~¡A¦p¤£µ¹¤©¿n·¥ªºªvÀø¡A³q±`·|«ùÄòªº´c¤Æ¡A¦Ó¦³­P©Rªº¦MÀI¡C2,7

¡@

ªí¤G¡B154¦ìµo¥Í°ª¤s¯f¥§ªyº¸®È«È¯gª¬¤À³¡±¡§Î

ÄY­««× ¦Ê¤À¤ñ ¯gª¬

»´«× 65 ÀYµh¡B¹½­¹¡Bäú¤ß¡B¥þ¨­­Â«å

¤¤«× 30 µLªk½w¸ÑªºÀYµh¡B¹Ã¦R¡B§¿¶q´î¤Ö

­««× 5 ·NÃѧïÅÜ¡B¨BºA¤£Ã­¡B¥ð®§®É©I§l§xÃø¡BªÍ³¡Å¥¨ìÅo

­µ¡BµoÖæ¡Bµø¨Å¬ð¤ô¸~

¡@

°ª¤sªÍ¤ô¸~¡ihigh altitude pulmonary edema(HAPE)¡j

°ª¤sªÍ¤ô¸~¡A¬O¤@ºØ«D¤ß¦]©ÊªÍ¤ô¸~¡A¸û©öµo¥Í©ó¨k©Ê¡C5-10%µo¥ÍAMSªÌ¡A·|µo¥Í°ª¤sªÍ¤ô¸~¡C¦b®È¦æ¦Ü®ü©Þ3,660¤½¤Øªº°ª¤s¡A¬ù¦³2%ªº¤H·|µo¥Í°ª¤sªÍ¤ô¸~¡A¦pªG¤£ªvÀø¡A¨ä¦º¤`²v¥i°ª¹F44%¡C2¤@¯ë¥¦µo¥Í©óµn¤W°ª¤sªº24-72¤p®É¤º¡A¦Ó¥H²Ä¤G­Ó±ß¤W³Ì±`µo¥Í¡C2,8³o¨Ç¯f±wªº¦å®ñ¤Î¯Ê®ñ´«®ð¤ÏÀ³(HVR)³q±`¸û§C¡A¦ÓªÍ°Ê¯ßÀ£«h©úÅã¦a¤É°ª¡AªÍ«´À£«h³q±`¥¿±`¡CªÍ¤ô¸~²Gªº¦¨¥÷¡A¦p¦¨¤H©I§lµ~­¢¯g­Ô¸s(ARDS)¤@¼Ë¡A³q±`§t¦³Â×´Iªº°ª¤À¤l¶q³J¥Õ½è¡AÅã¥Ü¨ä¬O¥Ñ©ó·L¦åºÞ³q³z©Ê§ïÅÜ¡A©Ò²£¥Í¦å¼ß²GÅ骺º|¥X¡C¦Ó»PARDS¤£¦Pªº¬O¡A¨äº|¥X²Gªº¤¤©Ê²y(neutrophil)«h³q±`¸û§C¡C2,4

°ª¤sªÍ¤ô¸~ªº¦­´Á¯gª¬¡A¥]¬A¹B°Êªí²{ÅÜ®t(±`¬O³Ì¦­ªº¯gª¬)¡B°®«y¡B¯h­Â¡B¤ß¸õ¥[³t¡B¥kªÍ¤¤¸­Å¥¨ìÅo­µ¡B¥H¤Î©I§l¥[³tµ¥¡C±ß´Áªº¼x­Ô¡A«h¥]¬A¥ð®§®É©I§l§xÃø¡B¦h·ðªº«y¹Â¡B·¥ºÝµê®z¥H¤ÎµoÖæµ¥¦Ó¨BºA¤£Ã­¡B¦æ¬°²§±`¡B·NÃѲV¶Ã¥H¤Î©ü°g¡A«h¥i¯à¬O¦]°ª¤sªÍ¤ô¸~ªº¯Ê®ñ©Ò²£¥Í¡AµM¥ç¥i¯à¥»¨­§Y¬O°ª¤s¸£¤ô¸~ªº¯gª¬¡C¤@¯ë¦Ó¨¥¡A¥u­n¯f±w¦³µn°ª¡A¥B¦³«y¹Â¡Bµê®z¡B¹B°Êªí²{ÅÜ®t¡B¥ð®§®É©I§l§xÃøµ¥¯gª¬¤¤¦Ü¤Ö¨â¶µ¡A¥H¤Î¦Ü¤Ö³æ°¼ªÍ¥iÅ¥¨ìÅo­µ©Î­ý³Ý­µ¡B¤¤¥¡©ÊµoÖæ(central cyanosis)¡B©I§l¥[³t¡B¤ß¸õ¥[³tµ¥¼x­Ô¤¤¦Ü¤Ö¨â¶µ¡A§Y¥i¶EÂ_¬°°ª¤sªÍ¤ô¸~¡C2,7

¨ä¨å«¬ªºX¥úªí²{¡A¬O«D¿Ä¦X©Êªºµ³¤òª¬ªÍ®û¼í(nonconfluent fluffy infiltration)¡F¨ä¤ßŦ¤j¤p³q±`¥¿±`¡A¦]¦¹¡A³q±`¤£·|¥X²{¤@¯ë¤ßŦ°IºÜ¡AªÍÀR¯ßÀ£¤É°ª©Òªí²{ªºKerleys lines¡FªÍ°Ê¯ß¸û¬ð¥X¡A³q±`¤£·|¥X²{¦Ø½¤¿n²G¡FªÍ®û¼í¥i¥H¬O³æ°¼©Î¨â°¼¡A¦Ó¥kªÍ¤¤¸­±`¬O³Ì¦­¥B³Ì±`µo²{®û¼íªº¦a¤è¡AªÍÅo­µ¤]±`³Ì¦­µo¥Í©ó¦¹³B¡C¦pªG¥ß§Yµ¹¤©ªvÀø(¯S§O¬O¤U¤s)¡AªÍ®û¼í³q±`·|¦b¤@¤Ñ¦Ü¼Æ¤Ñ¤º®ø¥¢¡A¦pªG¤´°±¯d¦b¦P¼Ëªº°ª«×¡AÁa¨Ïµ¹¤©¥ð®§¤Î®ñ®ðªvÀø¡AªÍ®û¼í³q±`¤]¤£®e©ö®ø¥¢¡C¤@¯ë¦b¤U¤s24-48¤p®É¤º¡A°µ¯Ý³¡X¥úÀˬd¡A¥i§@¬°½T©w°ª¤sªÍ¤ô¸~¶EÂ_ªº¤u¨ã¡C2,9

«P¦¨°ª¤sªÍ¤ô¸~ªº¦MÀI¦]¯À¡A¥]¬A§Ö³t¤W¤É¡B¼@¯P¹B°Ê¡BªÎ­D¡B¨k©Ê¡B¦³°ª¤sªÍ¤ô¸~¯f¥v¡B¥ý¤Ñ©Ê¯Ê¥kªÍ°Ê¯ß¡B¤ÎªÍ°Ê¯ßªñºÝ¯U¯¶µ¥¡C2,4¦p´¿¦³°ª¤sªÍ¤ô¸~¯f¥v¡A¨ä¦Aµo¥ÍªÍ¤ô¸~ªº¾÷·|¥i°ª¹F66%¡C10¦Ó¥­¤é©~¦í¦b°ª¤sªº°ª¤s¦P­M¡A¨Ã¤£·|¦]¦¹¹ï°ª¤s¯g§K¬Ì¡A¦p°ª¤s¦P­M¦b¥­¦a©~¦í¤F¤@¬q®É¶¡«á¡A¦A¦^¨ì°ª¤s¡A¤´µM¤]·|µo¥Í°ª¤s¯g¡C³oºØ²{¶H¦b¯µ¾|¤s°Ï¡A¥Ñ©ó¦b¦¹¤H­Ì«Ü®e©ö§Ö³t¤W¤É¨ì¸û°ªªº«°Âí¡A¦]¦¹³oºØ°ª¤s¯g¸g±`µo¥Í¡C4

¡@

°ª¤s¸£¤ô¸~¡ihigh altitude cerebral edema(HACE)¡j

°ª¤s¸£¤ô¸~¡A³q±`©ó²£¥Í»´«×«æ©Ê°ª¤s¯f«á¡A1-3¤Ñµo¥Í¡A¦ý¥i¦b12¤p®É¤º¡A¥Ñ»´«×°ª¤s¯fºtÅܬ°¬°ÄY­«ªº°ª¤s¸£¤ô¸~¡C2¦]¦¹³\¦h¾ÇªÌ»{¬°¡A°ª¤s¸£¤ô¸~¥i»¡¬O«æ©Ê°ª¤s¯fªº¥½´Á¯fÅÜ¡C4³\¦h°ª¤s¸£¤ô¸~ªº¯f±w¡AÁöµM¨Ã¨S¦³°ª¤sªÍ¤ô¸~ªº¯gª¬¥X²{¡A¦ý¯Ý³¡X¥ú¤Î¯f²z¸Ñ­åÀˬd¡A«o±`¦X¨Ö°ª¤sªÍ¤ô¸~¡CÅã¥Ü°ª¤s¯g¤¤©Ò¤À¥X¨Óªº«æ©Ê°ª¤s¯f¡B°ª¤sªÍ¤ô¸~¡B°ª¤s¸£¤ô¸~¡B°ª¤sµøºô½¤¯fÅܵ¥¡A¥i¯à³£¬O¦P¤@¯e¯fªº¤£¦Pµ{«×ªí²{½}¤F¡C2

°ª¤s¸£¤ô¸~¡A¤@¯ë«Ü¤Öµo¥Í©ó3,000¤½¤Ø¥H¤Uªº°ª«×¡C¦Ó§Ö³t¤W¤É¡A«h¬O²£¥Í°ª¤s¸£¤ô¸~³Ì­«­nªº¦]¯À¡C7¨ä¥D­n¯f²z¾÷Âà¡A³Q»{¬°¬O¦]¯Ê®ñ¡A¨Ï±o¸£¦åºÞÂX±i¡B¸£¦å¬y¶q¼W¥[¡B¸£·L¦åºÞÀR¤ôÀ£¼W¥[¦Ó²£¥Í¡F¨ä¯f²zÅܤƫD±`Ãþ¦ü°ª¦åÀ£¸£¯fÅÜ(hypertensive encephalopathy)¡C¨ä¨å«¬ªº¯gª¬¡A¥]¬AÄY­«ªºÀYµh(±`·|¦]¨«¸ô¡B¥Î¤O©Î¥­½ö¦Ó¥[­«)¡B¨BºA¤£Ã­¡i¤×¨ä¬OÂß·F¨BºA¤£Ã­(truncal ataxia)¡j¡Bäú¤ß¡B¹Ã¦R¡B§PÂ_¤O²§±`¡B¦æ¬°²§±`¡B¤Ûı¡B·NÃѲV¶Ã¡B¥H¦Ü©ü°g¡CµM³æ°¼ªÏÅéµL¤O©Î§½³¡¯«¸g¼x­Ô¡A°¸¦Ó¥ç·|µo¥Í¡C¦]¦¹¥²¶·»P¨ä¥¦¤¤¼Ï¯«¸gªº¯e¯f¦p¸£¤¤­·µ¥¡A§@Ų§O¶EÂ_¡C¤@¯ë¦Ó¨¥¡A¥u­n¯f±w¦³µn°ª¡A¨Ã¦X¨Ö¨BºA¤£Ã­©Î·NÃѧïÅܮɡA§Y¥i¶EÂ_¬°°ª¤s¸£¤ô¸~¡C2,11

¦b°ª¤s¸£¤ô¸~ªº¯gª¬¤¤¡A¨BºA¤£Ã­¡A³Q»{¬°¬O³Ì­«­n¥B³Ì¦³¥Îªº¦­´ÁÁ{§É«ü¼Ð¡C¦b¤s¤W¡A¦pµo²{¥ô¦ó¤@¦ì¶¤¤Í¡A¦³¨BºA¤£Ã­¡A¨«¸ô·n·n®Ì®Ì®É¡AÁa¨Ï¥L¨S¦³¨ä¥¦ªº¯gª¬¡A³£À³¥ý»{©w¥L¤wµo¥Í°ª¤s¸£¤ô¸~¡A¦ÓÀ³¥ß§Y¤U¤s¡C2¦Ó¨BºA¤£Ã­ªº¦­´Áµo¥Í¡A«hªí¥Ü¤p¸£¹ï¯Ê®ñ¡A³q±`¬O¸û±Ó·Pªº¡C8

ªvÀø

¥Ñ©ó°ª¤s¯g¡A¥i¦b¯gª¬¥X²{«á¤£¤[¡A§Y§Ö³t¥[­«¡C¦]¦¹¦­´Áĵı¡B¦­´Á¶EÂ_¡A¤´¬O¦¨¥\ªvÀøªºÃöÁä¡A¨äªvÀøªº¥D­n­ì«h(¦pªí¤T)¬°¡G7

1.Â÷¶}°ª«×Àô¹Ò(¤U¤s)

2.ÁB¥¿²£¥Í¯gª¬ªºÀô¹Ò(µ¹¤©®ñ®ð¡B¼W¥[Àô¹ÒÀ£¤O)

3.¥ð®§(´î¤Ö®ñ®ð®ø¯Ó)

4.ÃĪ«ªvÀø(Áö½T¦³¨ä¥\®Ä¡A¦ý¤´À³·í§@»²§UªvÀø¡C)

­°§C°ª«×¡A¥Ø«e¤´¬OªvÀø°ª¤s¯g¡A³Ì­«­n¥B³Ì¦³®ÄªºªvÀø¡CÁöµM»´«×°ª¤s¯g¡A¥i¥H¤£¥²¥ß§Y¤U¤s¡A¦Ó¯à¦b¦P¼Ë°ª«×¤U¡A¸g¹L¾AÀ³¦Ó¨Ï¯gª¬§ïµ½¡A¦ý¦p¸g¹L¤G¤Q¥|¤p®É¾AÀ³©ÎªvÀø¡A¤´µL§ïµ½®É¡A«hÀ³¥ß§Y¤U¤s¡CÁöµM­°§C°ª«×­°±o¶V¦h¶V¦n¡A¦ý¤@¯ë­°§C500-1000¤½¤Ø¡A§Y¨¬¥H¨Ï¯gª¬§ïµ½(¹ï©ó»´«×°ª¤s¯g¯f±w¡A³q±`¥u­n¤U­°70¦Ü140¤½¤Ø¡A¯gª¬§Y¥i§ïµ½)¡C¦p¦³ÄY­«ªº¯gª¬¡A¦p°ª¤s¸£¤ô¸~¡]¨BºA¤£Ã­¡B·NÃѤ£²M¡^¡B°ª¤sªÍ¤ô¸~µo¥Í®É¡A«hÀ³¥ß§Y¤U¤s¡C2

¦pµLªk¥ß§Y¤U¤s¡A°£¤Fµ¹¤©®ñ®ðªvÀø¥~(³q±`Äâ±a¤£«K¡A¦ý²{¦b¤w¦³­«¶q¸û»´ªº¾T¦Xª÷®ñ®ð²~©Î®ñ®ð»s³y¾÷¡A±N¦³§U©óÄâ±a)¡A²{¦b¦³¤@ºØÄâ±a¦¡¥[À£³U(portable hyperbarbic bag or Gamow bag)8¡i5.5¤½¤ç­«¡A±i°_¨Ó¹F2.1¤½¤Øªø¡A¥b®|0.81¤½¤Ø¡A¥Î¸}½ñ¥[À£¡A¥i¦b3-4¤ÀÄÁ¤º¡A±N³U¤ºÀ£¤O¡A¥[À£¦Ü°ª©ó©P³òÀô¹Ò100²@¦Ì¨E¬WªºÀ£¤O¡C¥iÅý°ª¤s¯g¯f±w¶i¤J¡A¦p¥[À£¦Ü°ª©ó©P³òÀô¹Ò120²@¦Ì¨E¬W®É¡A¬ù¬Û·í©ó¤U­°1,432¤½¤Ø¡A¹ï©ó¯gª¬ªº§ïµ½¡A¥i¬Û·í©ó¨C¤ÀÄÁ¥|¤½¤Éªº®ñ®ðµ¹¤©¡]FiO2 30-40%¡^¡C¡j¡A¥i¦bµo¥Í°ª¤s¯g®É¡A§@¬°¼È®ÉªvÀø¤§¥Î¡C¥Ñ©ó¥[À£³U¤@¯ë¸û»´¡B¥iºPÅ|¡B¥i­«½Æ¦h¤H¨Ï¥Î¡B¥B¤£·|¹³®ñ®ð·|³vº¥¥Î§¹¡A¦]¦¹¤@¯ë«ØÄ³¡A¦pµn¤s¶¤­n¤W15,000­^§`(4,575¤½¤Ø)¥H¤Wªº°ª¤s¡A¶¤¥î¤¤À³·Ç³Æ¤@­Ó¥[À£³U¡C12

ÃĪ«¤è­±¡A¥Ø«e³QÃÒ¹ê¡A¹ïªvÀø¤Î¹w¨¾°ª¤s¯g¦³®ÄªºÃĪ«¡A¥]¬Aacetazolamide, dexamethasone, nifedipine¡Cacetazolamide¬O¤@ºØºÒ»Ä¶o×Q(carbonic anhydrase)ªº§í¨î¾¯¡A¨ä§@¥Î¾÷Âà¡A¥i¯à¬O¦]¦³«P¶iºÒ»Ä±Æ°£ªº§Q§¿§@¥Î¡A²£¥Í»´«×ªº¥NÁ©ʻĦå¯g¡A¦Ó¨ë¿E©I§l¼W¥[´«®ð¨ÏPaO2¤W¤É©Ò²£¥Í¡A¦P®É¥¦¤]·|´î¤Ö¸£¯áÅè²Gªº²£¥Í¨Ã´î¤Ö¨äÁ`¶q¡A¤wÃÒ¹ê¹ïªvÀø¤Î¹w¨¾°ª¤s¯g¦³®Ä ¡CÃþ©T¾Jdexamethasone¨ä§@¥Î¾÷Âà¥Ø«e¤´¤£²M·¡¡A»{¬°¥i¯à¬O¦]§ïµ½·L¦åºÞ²Ó­M½¤ªº§¹¾ã©Ê¡A¨Ï¸£¦åºÞ¦¬ÁY¡A¹ï°ª¤s¸£¤ô¸~¤Î¤¤«×¥H¤Wªº°ª¤s¯f¦³ªvÀø®Ä¡C¶tÂ÷¤lªýÂ_¾¯nifedipine¥i¦³®Ä´î¤ÖªÍ¦åºÞªý¤O¤ÎªÍ°Ê¯ßÀ£¡AÃÒ¹ê¹ïªvÀø°ª¤sªÍ¤ô¸~¦³®Ä¡C¨ä¥LªºÃĪ«¡A¦p§Q§¿¾¯ Furosemide(lasix)¨C12¤p®Éµ¹¤© 80²@§J¡A¥ç¥i¦³®ÄªvÀø°ª¤s¯f¡B°ª¤s¸£¤ô¸~¡B°ª¤sªÍ¤ô¸~¡A¦ýÀ³¯d·N¯f¤H¬O§_¦³²æ¤ôªº²{¶H¡A¥H¨¾¤î¥ð§Jµo¥Í¡C¦¹¥~¤î¦RÃÄProchlorperazine(novamine)°£¤F¥i§ïµ½äú¤ß¡B¹Ã¦Rªº¯gª¬¥~¡A¤]·|¼W±j¯Ê®ñ´«®ð¤ÏÀ³(HVR)¨Ï´«®ð¼W¥[¡A§ïµ½¦å®ñ¹¡©M«×¡C2,4,7,8,12,13

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

ªí¤T¡B°ª¤s¯gªvÀø­ì«h

»´«×°ª¤s¯g

°±¤î¤W¤É ¥ð®§ ¾AÀ³¦Pµ¥°ª«×

Acetazolamide, 125-250 mg bid(¥[³t¾AÀ³)

¯gª¬ªvÀø(¤îµh©Î¤î¦R¾¯)©Î¤U­°500¤½¤Ø¥H¤W

¡@

¤¤«×°ª¤s¯g

§C¬y¶q®ñ®ð(¦p¦³ªº¸Ü)

Acetazolamide, 125-250 mg bid³æ¿W©Î¦X¨Ö

Dexamethasone, 4 mg po, IM or IV q6h

©Î¥ß§Y¤U­°

¡@

°ª¤s¸£¤ô¸~

¥ß§Y¤U­°

®ñ®ð, 2-4 L/min

Dexamethasone, 4 mg po, IM or IV q6h

°ªÀ£¿µªvÀø

¡@

°ª¤sªÍ¤ô¸~

¬¡°Ê¶q´î¨ì³Ì§C¨Ã«O·Å

®ñ®ð, 4-6 L/min §ïµ½«á§ï¬° 2-4 L/min

Nifedipine, 10 mg ¤fªAµø¤ÏÀ³¨C¥|¤p®Éµ¹¤©

©Î10 mg¤fªA«á¨C12-24¤p®Éµ¹¤©ªø®Ä«¬»s¾¯

°ªÀ£¿µªvÀø

¥ß§Y¤U­°

¡@

¶g´Á©Ê©I§l

Acetazolamide, 62.5-125 mgµø»Ý­nºÎ«eµ¹¤©

­¸¯è«æ¯g

ÀHµÛÂå¾Ç¶i¨B¡B°ê¤H¥Í¬¡¤ô·Ç´£°ª¡A¥X°ê®È¹C½«¬°­·®ð¡A¦UºØºC©Ê¯e¯f¯f±wµn°ª©Î·f­¸¾÷¥X°ê®È¹Cªº¾÷·|¡A±N¤j¬°¼W¥[¡CµMÀHµÛ°ª«×ªº¤É°ª¡A¤j®ðÀ£¤O¤Î®ñ®ð¤ÀÀ£¡A·|³vº¥­°§C¡C¦Ó¤@¯ë°Ó¥Î«È¾÷¡A¦b¨ä³Ì¬Ùªoªº­¸¦æ°ª«×(28,000-43,000­^§`)¡A¨ä¾÷¿µ¤ºÀ£¤O¤Î®ñ®ð¤ÀÀ£¡A¤]¸û¥­¦a§C¡A¦b35,000­^§`ªº­¸¦æ°ª«×¡A¤HÅé°Ê¯ß¦å¤¤ªº®ñ®ð¤ÀÀ£¡A¤j¬ùµ¥©ó¥­¦aªº70%¡A14³o¼Ëªº§C¦å®ñ¡A¹ï©ó¥¿±`¤H³q±`¥i¥H¾AÀ³¨}¦n¡A¦ý¹ï©ó¤@¨Ç¦³¯fªº¤H¡A«o¥i²£¥ÍÄY­«ªº¼vÅT¡C®Ú¾Ú¬ü°êªº²Î­p¡AºC©Êªý¶ë©ÊªÍ¯e¯f±w¡A¦b­¸¾÷¤W¦³18%ªº¤H¡A¯gª¬·|¥[­«¡A¨ä¥L¦p«aª¬°Ê¯ß¯e¯f¡B¤ßŦ°IºÜ¡BªÍ°Ê¯ß°ªÀ£¡B¼È®É©Ê¸£¯Ê¦å¡B¸£¤¤­·¡BÅöíw¡B¸£½F¡BÅI§Î¦å²y¯g¡B¦å®ê¯g(¸gÀÙ¿µ¯g­Ô¸s)¡B¤líw«e¯gµ¥¯e¯f¡A¦b°ª¤s¤Î­¸¾÷¤W¡A¨äµo§@©Î¯gª¬¥[­«ªº¾÷·|¡A½T¹ê¸û¥­¦a¬°°ª¡C¦Ó¨äªvÀø­ì«h¤]©M¤@¯ë°ª¤s¯g¤@¼Ë¡A¬O¥H­°§C°ª«×¤Îµ¹®ñ¬°¥D¡C¹ï©ó¤@¯ë±ÏÅ@ª½ª@¾÷«h¬O¨S¦³¥[À£¿µªº¥[À£¥\¯à¡AµM¥Ñ©ó¨ä­¸¦æ°ª«×ªº­­¨î¡A«Ü¤Ö­¸¶W¹L12,000­^§`(3658¤½¤Ø¡^ªº°ª«×¡A¦ý¹ï©ó¦³¯fªº¤H¡A«o¤´¥i³y¦¨ÄY­«ªº¼vÅT¡C1,14,15,16

¹w¨¾

¹w¨¾³Ó©óªvÀø¡A½wºC¤W¤É¡AÅý¨­Å馳¨¬°÷ªº®É¶¡¥h¾AÀ³°ª«×ªºÅܤơA¤´¬O¹w¨¾°ª¤s¯g³Ì­«­nªº·Ç«h¡C¥Ñ©ó±ß¤WºÎı®É¡A°Ê¯ß¦å®ñ·|­°±o§ó§C(¬Û·í©óµn¤W§ó°ªªº°ª«×)¡A¦]¦¹±ß¤WºÎıªº¦aÂI¡A¦p¯à§C©ó¥Õ¤Ñ¬¡°Êªº°ª«×¡A±N¸û¯àÁ×§K°ª¤s¯gªº²£¥Í¡C2,7

¦¹¥~¡A¦pÄâ±a®ñ®ð©ÎÄâ±a¦¡¥[À£³U¡BÁ×§K¼@¯Pªº¬¡°Ê¡B«O·Å(§CÅé·Å·|¥[­«°ª¤s¯g)¡B¤£­n§lµÒ(·|´î¤ÖªÍªº®ñ®ðÀò±o¡B¨Ã¼W¥[ªÍ°Ê¯ßÀ£)¡B¤£­n³Ü°s¤ÎªA¥ÎÂíÀR¾¯(·|§í¨î©I§l¤¤¼Ï¤ÎHVR¡A¦]¦¹°ª«×¦b2,440¤½¤Ø¥H¤W®ÉÀ³Á×§K¨Ï¥Î¡C)¡B¦Y°ªºÒ¤ô¤Æ¦Xª«(©I§l°Ó¸û°ª¡A¥i²£¥Í¸û°ªªºªÍªw®ñ¤ÀÀ£(PAO2)¡C¦P®É¡A·|²£¥Í¸û¦h¶qªº¤G®ñ¤ÆºÒ¡A¯à¦b°ª¤s¯Ê®ñªºÀô¹Ò¤U¡A¨ë¿E©I§l¡C)¡BÁ×§K¦Y²£®ð­¹ª«¦p¨§Ãþ©ÎºÒ»Ä¶¼®Æ(¥H´î¤Ö¦]´îÀ£®ðÅ鿱µÈ©Ò²£¥Íªº­Gº¦®ð¡A¸¡³¡¤â³N«á¥i¦]­Gº¦®ð¡A¦Ó¨Ï­ì¨ÓÁ_¦Xªº¶Ë¤f¯}µõ¡C)¤Î§C¯×¡B§CÆQªº­¹ª«¡A³£¥i´î»´©ÎÁ×§K°ª¤s¯gªºµo¥Í¡C2,4,8

ÃĪ«¤è­±¡A¥Ø«e³QÃÒ¹ê¹ï¹w¨¾°ª¤s¯g¦³®ÄªºÃĪ«¥]¬Aacetazolamide, dexamethasone, nifedipine¡C¹ï©ó¥²»Ý§Ö³t¤W¤É¡A«o¨S¦³¨¬°÷ªº®É¶¡¥i¾AÀ³°ª«×ªÌ¡A¥i©ó¤W¤É«e24¤p®É¡A§Y¶}©lªA¥Îacetazolamide 250²@§J¡A¤@¤Ñ¨â¦¸©Î¤@¤Ñ¤@¦¸ºÎ«eªA¥Î¡A¨Ã¦Ü¤Ö«ùÄòªA¥Î¦Ü¤W¤É«á2-3¤Ñ¡C¹ï©óÁD»Ï¾¯¹L±ÓªÌ¡A¥i¨C12¤p®É¨Ï¥Îdexamethasone 4 ²@§J¡A¨Ã¦Ü¤Ö«ùÄòªA¥Î¦Ü¤W¤É«á2-3¤Ñ¡A¥Ñ©ódexamethasoneªºÄY­«°Æ§@¥Î¡A¦p°ª¦å¿}¡B¸z­G¹D¥X¦åµ¥¡A¥H¤Î·|¦b°±ÃÄ«á¡Aµo¥Í¤Ï¼u©Ê°ª¤s¯gªº²{¶H¡A¦]¦¹¤@¯ë§â¥¦·í§@²Ä¤G½u¹w¨¾ÃĪ«¡Cnifedipine¤wÃÒ¹ê¥i­°§CªÍ°Ê¯ßÀ£¡B§ïµ½¦å®ñ¹¡©M«×¡B¨Ã¹w¨¾°ª¤s¯f¤Î°ª¤sªÍ¤ô¸~ªºµo¥Í¡A¨Ï¥Î¾¯¶q¬°ªø®Ä«¬nifedipine 20²@§J¡A¨C¤K¤p®ÉªA¥Î¤@¦¸¡C2,4,13

¹ï©ó´¿¦³°ª¤s¯f¯f¥vªÌ¡AÀ³¥ý¦b­ì¨Óªº°ª«×©Î¸û§Cªº°ª«×¡A«Ý¦Ü¤Ö¨â¤Ñ¥H¤W¡Aµ¥¯gª¬®ø¥¢«á¤~¥i¦A¤W¤É¡A¦p¦³°ª¤sªÍ¤ô¸~©Î¸£¤ô¸~µo¥Í®É¡A«hÀ³¥ß§Y¤U¤s¡A¥HÁ×§K·N¥~µo¥Í¡C2

¹ï©óºC©Ê¯f¯f±w¡A«hÀ³¤F¸Ñ¨ä¯fªp¡Aµø±¡ªp³\¥i¡A¤~¥iµn°ª¡C

¡@

¤sÃøºò«æÂåÀø±ÏÅ@¨t²Î

§Ú­Ìª¾¹D¤U¤s¬O°ª¤s¯g¤Î¤sÃø±ÏÅ@¦¨¥\ªº³Ì­«­n¦]¯À¡AµM¦b«e¤£µÛ§ø¡B«á¤£µÛ©±¡B¹D¸ô±T¹òªº¤s¤¤¡A·Q­n§Ö³t¤U¤s¡A«o¬O¬Û·í§xÃøªº¡C§¹µ½ªººò«æÂåÀø±ÏÅ@¨t²Î¡A«h¥i¦³®ÄÁYµu±Ï´©ªº®É¶¡¡A¼W¥[¦s¬¡ªº¾÷·|¡C

¤sÃø±Ï´©¦¨¥\»P§_¡A¨ú¨M©ó¤U¦C´X­Ó¦]¯À¡G¦p¦³¦³®Äªº³q°T¡B¦³®Äªº¹B¿é¡B¦³®Äªº±Ï¥X(¦p¥Îµ±½L©Ô°_)¡B¦³®ÄªºÂåÀø·ÓÅ@¡A«h¥i¼W¥[±Ï´©¦¨¥\ªº¾÷·|¡F¦ý¦p±Ï´©®É¶¡¶Vªø¡B¶Ë®`¶VÄY­«¡B¤Ñ­Ô¶V®tµ¥¦]¯À¡A«h¤£§Q©ó¤sÃøªº±ÏÅ@¡C¨ä¤¤¤Ñ­Ô¤Î¶Ë®`ªºÄY­««×µLªk¥Ñ¤H¬°±±¨î¡AµM¨ä¥¦¶µ¥Ø¦p¦³®Äªº³q°T¡B¹B¿é¡B±Ï¥X¡BÂåÀø·ÓÅ@¤ÎÁYµu±Ï´©®É¶¡µ¥¡A«h¥i¸g¥Ñ³W¹º§¹µ½ªººò«æ±ÏÅ@¨t²Î¡A¦Ó¼W¥[±Ï´©¦¨¥\ªº¾÷·|¡C2,8

¦]¦¹§¹µ½ªººò«æÂåÀø±ÏÅ@¨t²Î¡A¬O¤sÃø±ÏÅ@¦¨¥\ªºÃöÁä¡C¥Ø«eÃö©ó¤sÃøªººò«æÂåÀø±ÏÅ@¨t²Î¡A·ç¤hªüº¸¨õ´µ¤s°Ïºâ¬O¸û§¹µ½ªº¤@°Ï¡A³oùبC¦~¦³¤@»õ¤H¦¸ªº¹C«È¡A¦b³\¦h¦a°Ï¡A¨ä¤sÃøµo¥Íªº¦¸¼Æ¡A¤ñ¥æ³q¨Æ¬GÁÙ¦h¡C¨C¦~¬ù¦³1,500¦¸±Ï´©¡A¨ä¤¤¦³¶W¹L90%ªº±Ï´©¡A¬O¥Ñª½ª@¾÷¨Ó¾á¥ô±Ï´©ªA°È¡]¦b¬ü°ê«h¥H®{¨B¬°¥D¡A¨ä¥D­n°Ñ»P¤H­û¬°µn¤s©Î·Æ³·¤H¤h¡C¡^¡A¦Û1952¦~¥H¨Ó¡A¤w±Ï¥X¶W¹L150,000­Ó¯f¤H¡C¥L­Ì¦³¤@­Ó¤G¤Q¥|¤p®ÉªA°Èªº¤sÃø±ÏÅ@«ü´§¤¤¤ß¡A¦³¤@­Ó¥i¨ç»\¾ã­Óªüº¸¨õ´µ¤s°Ï¥B¨S¦³¦º¨¤ªº³q°Tºô¸ô¡A¦P®É¡A¥L­Ì¦³¤@­Ó±K¶°ºôª¬ªº±Ï´©¯¸¡A¦pÁҰϤº¦³¥ô¦ó¤@­Ó¦a¤èµo¥Í¨Æ¬G¡Aª½ª@¾÷¥i¦b15¤ÀÄÁ¤º¨ì¹F¥ô¦ó¥i¯àªº¥X¨Æ¦aÂI¡Cª½ª@¾÷¥iµÛ¸ô©Î¥Hµ±½L©Ô°_¯f±w¡A¹ï©ó§xÃøªº¦a§ÎªºÀç±Ï¡A¦³¶W¹L95%ªºÀç±Ï¬OÂǵ۵±½L¡]¥i¦ù¥X120¤½¤Ø¡^±N¯f±w©Ô°_±Ï¥X¡Cª½ª@¾÷¤Wªº¤H­û°t¸m¡A¦b·ç¤h­ì«h¤W¬O¤@¦ìÂå®v¤Î¤@¦ì°ª¤sÂQ¾É¡]¨ä¤¤¯u¥¿¥ÑÂå®v°Ñ»PªÌ¶È¥e8%¡^¡C¦b¬ü°êª½ª@¾÷¤Wªº¤H­û°t¸m«h¥]¬A¤@¦ìÅ@²z¤H­û¡]¨ü¹L«æ±Ï§Þ³N­û°V½m¡^¤Î¤@¦ì¥i¬°Âå®v¡BÅ@²z©Î°ª¯Å«æ±Ï§Þ³N­û¡]EMT-P)ªº¤H­û¡C¦Ü©ó¦óªÌ¤H­û°t¸m¸û¨Î¡A¥Ø«e¤´µL©w½×¡A¤´¦³¤@¨Ç³ø§iÅã¥Ü¦³Âå®v°Ñ»P©M¥u¦³Å@²z¤H­û©ÎEMT-P¨Ó¤ñ¸û¡A¨Ã¨S¦³©úÅã§ïµ½¯f¤Hªº¹w«á¡AµM©Òªá¶Oªº¦¨¥»«h½T©w´£°ª¡Cªñ¦~¨Ó¦b¬ü°êEMT-P°Ñ»Pª½ª@¾÷±ÏÅ@ªº¤ñ²v³v¦~¤W¤É(¥Ñ1988¦~ªº44%¼W¦Ü1993ªº71%)Âå®v°Ñ»Pªº¤ñ²v«hº¥´î¤Ö¡]¥Ñ1988¦~ªº10%­°¦Ü1993ªº3%¡^¡i¨ä¤¤¥Ñ¨ü¹L°V½mªºÂåÀø¤H­û°Ñ»P¡A¥i±N±ÏÅ@´£¦­¨ì±q¦b²{³õ§Y¶}©l¡C¥H·ç¤h¬°¨Ò¡A³o¨ÇÂå®v¥²¶·±µ¨üÂåÀø°V½m¤Î§Þ³N°V½m¡A¦bÂåÀø°V½m¤è­±¡A¥L­Ì¥²¶·¼ô½m¤º¡B¥~¬ì¤Î§xÃøª¬ªp¤Uªºªº«æ±Ï´_µd¡A¤Î®ðºÞ´¡ºÞªº¸m¤J¡F¦b§Þ³N°V½m¤è­±¡A¥L­Ì¥²¶·­º¥ý³Q°V½m¦¨¬°¤@¦ì¦³¸gÅ窺µn¤sªÌ¡A¦Û¤v¯à¦b¤s¤¤¦s¬¡¤Î²¾°Ê¡A¦Ó¤£·|¦¨¬°¨ä¥L¬I±ÏªÌªº²ÖÂØ¡C¦P®É¡A¥L­Ì¥²¶·¼ô±x¦UºØª½ª@¾÷±ÏÅ@ªº¤è¦¡¤Î¤u¨ã¨Ï¥Î¡A¨Ã¥]¬AÄa¦Q¦bª½ª@¾÷ªºµ±½L¤WÀç±Ï¡j¡i¥Ñ°ª¤sÂQ¾É°Ñ»P¡A¥Ñ©ó¨ä¹ï©ó¤s¤¤¦a§Î¸û¼ô±x¡A¥i¥[³t´MÀò¯f±w¡C¥H³·±Y¬°¨Ò¡A²Ä¤@¤p®É¦s¬¡ªº¾÷·|¤´¦³30-40%¡A©¹«á¨C¹L¤@¤p®É¡A¦s¬¡ªº¾÷·|­°§C10%¡A¥i¨£¦­´Á´MÀò¯f±w¡A¹ï¨ä¦s¬¡²v½T¦³ÃöÁä©Êªº¼vÅT¡A¦p¦³ª½¤É¾÷¥[¤W¼ô±x¦a§Îªº°ª¤sÂQ¾É¡A±N§ó¯à¥[³t´MÀò¯f±w¡C¡j9,16-9

°ê¤ºªº¤sÃøºò«æÂåÀø±ÏÅ@¨t²Î¡A¥Hµ§ªÌªº²L¨£¡A¦³´XÂI­È±o§Ú­Ì§ï¶iªº¦a¤è¡G1. ³q°T¨t²Î¥¼¿²§¹µ½(§¹³Æªº³q°T¨t²Î¡A¬Oºò«æÂåÀø±ÏÅ@¨t²Î¤¤³Ì­«­nªº¶µ¥Ø¡A¬O±ÏÃø¦¨¥\ªºÃöÁä¡C¥²¶·¥ý¦³¤H³ø®×¡A¤~¦³±ÏÃøªº¶i¦æ¡Aµ§ªÌ¿Ë±­¥h¦~µnªFÅr¤j¤s®É¡AÁöÄâ±a¤j­ô¤j¤Î­»¸z±ÚµL½u¹q³q¸Ü¾¹¡A¦ý¦]°ê¤º©|µL¨}¦nªº½Ã¬P³q°T¨t²Î¡A¬G¨ü¦a§Îªýê¡A¦b¤s¨¦¸Ì¤´µLªk»P¥~¬ÉÁpµ¸¡^2.¥¼¦³¨}¦nªºª½ª@¾÷±ÏÅ@¿ìªk¤Î¥¼¬I¦æ¨Ï¥ÎªÌ¥I¶O¡]¥Ø«e°ê¤º¤sÃø±ÏÅ@¡A¤´¥H¤H¤O®{¨Bµn¤s±ÏÅ@¬°¥D¡AÁö¦³¦h­Ó³æ¦ì¯à¬£»ºª½¤É¾÷¡A¦ý¥Ó½Ð¤âÄò¹L©óÁc½Æ¡A±`³à¥¢±Ï¤H¥ý¾÷¡C¦¹¥~¡A¨S¦³­q©w¨}¦nªºª½¤É¾÷¾AÀ³¯g¡B»{©w¼Ð·Ç¤Î¨S¦³¬I¦æ¨Ï¥ÎªÌ¥I¶O¡A¬G±`³Q¯SÅv©ÒÀݥΡCµMª½ª@¾÷±ÏÅ@¥»¨­§Y¬O¤@¦³¦MÀI¥B©ù¶Qªº±ÏÅ@¡A®Ú¾Ú¬ü°ê²Î­p¡A¨äªá¶O¬ù¬°³°¸ô±ÏÅ@ªº¥|­¿¡A¥­§¡¨C¤@¯f¤H¬ùªá¶O2,000¬ü¤¸¡C¦b·ç¤hªüº¸¨õ´µ¤s°Ï¡A¤Q¤­¦~¨Ó¡A¦@¦³¤T¥ó±ÏÅ@ª½ª@¾÷åP¾÷¨Æ¥ó¡A¥i¨£¨ä¤´¬O¦³¦MÀIªº¡C2¬G¬I¦æ¨Ï¥ÎªÌ¥I¶O¡AÀ³¥i¦³®Ä´î¤Ö¨äÀݥΡ^3.¥i¦Ò¼{¦bª½ª@¾÷¤W°t¸m°ª¤sÂQ¾É(²¦³º¦h¼Æªº­¸¦æ­û¤´¤£¬O¦³¸gÅ窺µn¤sªÌ¡A¨Ã¤£¼ô±xµn¤s¸ô½u¤Î¦a§Î¡A¦p¦³°ª¤sÂQ¾É°Ñ»P¡A¥Ñ©ó¨ä¼ô±xµn¤s¸ô½u¤Î¦a§Î¡A±N¥[³t´MÀò¯f±w)4.¥i¦Ò¼{¦bª½ª@¾÷¤W°t¸m¨ü¹L°V½mªºÂåÀø±ÏÅ@¤H­û¡]¦pÂå®v¡BÅ@²z¤H­û©Î°ª¯Å«æ±Ï§Þ³N­û¡A¥H«K¦³®Ä¦a±N±ÏÅ@´£¦­¦Ü¨ìÂå°|«e§Y¶}©l±ÏÅ@¡C¥Ø«e°ê¤º¤w¦³¥ÁÀç±ÏÅ@ª½ª@¾÷°t¸m¦³Å@²z¤H­û¡A¦ý¥¼³W©wÀH¾÷¤H­ûªº±ø¥ó¡A¦b¬ü°êÀH¾÷ªºÅ@²z¤H­û»Ý¦³«æ¶E©Î¥[Å@ªº¸gÅç¡A¥B»Ý¨ü¹L°ª¯Å¤ßŦ±Ï©R³N¡B°ª¯Å½H¶Ë±Ï©R³N¤Î¤p¨à°ª¯Å±Ï©R³N°V½m¡^5.¥¼¦³±M¾³æ¦ì¥D¾É«ü´§¤sÃø±ÏÅ@¡]¥Ø«e¥D­n¥Ñĵ¹î³æ¦ì«ü´§¡AÁöµM¨ä«D±`»{¯u°õ¦æ¡A¥B±`¾Ä¤O®{¨B¤W¤sÀç±Ï¡AµM²¦³º¦h¼ÆªºÄµ¬F¤H­û¡A¨Ã¤£¼ô±xµn¤s¸ô½u¤Î¦a§Î¡A¥B¥Ø«e°ê¤ºÄµ¬F¤H­û¤´¸g±`½ü½Õ¡A¹ï·í¦a¦a§Îµy·L¼ô±x¡A§Y¤w½Õ©¹¥L³B¡C¬G¥H­Ó¤H²L¨£¡A¦p¥Ñ¤@¨Ç»P¤j¦ÛµM¬°¥îªº³æ¦ì¡A¦p¥É¤s°ê®a¤½¶éºÞ²z³B¡B¤Ó¾|»Õ°ê®a¤½¶éºÞ²z³B©Î³·ÅQ°ê®a¤½¶éºÞ²z³Bµ¥¡A¨Ó¥D¾É«ü´§¤sÃø±ÏÅ@¡A¥i¯à§ó¬°±Mºë¡^6.¥¼¦³§¹µ½ªº«ü´§¤¤¤ß¤Î¤sÃø±ÏÅ@¿ìªk¡]¦b¨Æ¥óµo¥Í¡A¥Á²³¥´119¹q¸Ü¡A»{©w¬O¤sÃø¨Æ¥ó«á¡A¥ß§Y¯à¦³¤@³s¦êªº¤ÏÀ³¤Î¦h­Ó³æ¦ì»Ý­nÁpµ¸¡A¶·¦³¨}¦nªº«ü´§¤¤¤ß¡C¦P®É¡A©y­q©w¼Ð·Çªº¤ÏÀ³¼Ò¦¡¡A¥H«K¥ô¦ó¨Æ¥óµo¥Í¡A¦b¥ô¦ó¤H­È¯Z®É¡A³£¦³¤@®M§Ö³t¤ÏÀ³ªº¼Ò¦¡¡A¯à§Ö³t¦³®Äªº±Ï¥X¯f±w¡C¡^2,3

¦¹¥~¡A¹ï©ó¸g±`¦³¤s¤Í¥X¤J¡A¤S®e©öµo¥Í¤sÃøªº¦a¤è¡A¥i¦b¾Fªñªº¤s«Î¡A³]¸m«æ±Ï³]¬I¡A¦p»OÆW¥É¤sªº±Æ¶³¤s²ø¡B©_µÜªº©_µÜ¤s²ø¡B³·¤sªº369¤s²øµ¥¦a¡A³]¸m¦p®ñ®ð¡B¥[À£³U¤Î«æ±Ï³]¬Iµ¥¸Ë³Æ¡A¨Ã¦b°ª¤sÂQ¾É°V½m®É¡A±N³o¨Ç«æ±Ï¾¹§÷ªº¨Ï¥Î¡A¦C¤J°V½m½Òµ{¡A¦p¦¹À³¦³§U©ó°ê¤º°ª¤s¯g¤Î¤sÃøªº±ÏÅ@¡AÁ×§K¤£©¯ªºµo¥Í¡C

¡@

µ²»y

¦b¥æ³q¤u¨ãµo¹F¡B®È¹C½«¬°­·®ðªº¤µ¤Ñ¡A°ª¤s¯g¤w¤£¦A¬Oµn¤sªÌªº±M§Q¡A¥¦¤]µo¥Í¦b³\¦h­¼­¸¾÷¡B¨T¡B¾÷¨®§Ö³t¤W¤s¡A©Î¬Æ¦Ü¥u¬O¥X°ê®È¹Cªº¤H­Ì¡C¨Æ¥ýªº¹w¨¾¡B¦­´Á¶EÂ_¤ÎªvÀø¡A¤´¬OÁ×§K¤£©¯¨Æ¥óªº¤£¤Gªkªù¡C¥Ñ©óÂå¾Çªº¶i¨B¡A³\¦hºC©Ê¯f¯f±w¡A¦³§ó¦hªº¾÷·|¡A±o¥H­¼§¤­¸¾÷©Î¨T¡B¾÷¨®¥hÆ[¥ú®È¹C©Îµn¤s¡A¤j®a¥i¯à¦b¤£¸g·Nªºª¬ªp¤U¡A§Y¤wµn¤W¨¬¥Hµo¥ÍÄY­«°ª¤s¯gªº°ªªÅ¡C¦]¦¹¡A°ß¦³¼W¥[¦U¬É¹ï°ª¤s¯gªº¤F¸Ñ¡A¦@¦P«Ø¥ß§¹µ½ªººò«æ±ÏÅ@¨t²Î¡A¤~¥iÁ×§K¤£©¯¨Æ¥óªºµo¥Í¡AÅý¤j®a¦bªY½à¬ü´º¡B¿Ëªñ¤j¦ÛµM¤§¾l¡A¯à°ª°ª¿³¿³ªº¥Xªù¡A¥­¥­¦w¦wªº¦^®a¡C

¡@

°Ñ¦Ò¤åÄm:

  1. ¿ú¤¸±d. ±qµn¤sÂå¾Ç¤ÀªR¤ñ¸û°ê¤º¥~¤sÃø. ¥É¤s°ê®a¤½¶é¤sÃø¨¾±Ï¬ã°Q·|±M¤å¶°¡A1991¡C
  2. Auerbach PS: High altitude medicine. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed.1995; 1-37
  3. °ª°¶®p¡B­J³Ó¤t¡B§õ«Ø½å. °ª¤s¯g¡CÁ{§ÉÂå¾Ç 1995; 36: 35_50
  4. Bezruchka S. High altitude medicine. Medical Clinics of North America 1992; 76: 1481-97.
  5. Montgomery AB, Mills J, Luce JM. Incidence of acute mountain sickness at intermediate altitude. JAMA 1989; 261:732-4.
  6. Hackett PH, Rennie ID. Rales, peripheral edema, retinal hemorrhage and acute mountain sickness. Am J Med 1979; 67:214-8.
  7. Tom PA, Garmel GM, Auerbach PS: Environment-dependent sports emergencies. Med Clin North Am 1994 Mar; 78(2): 305-25.
  8. Volloton J, Dubas F: A color atlas of mountain medicine. Wolfe pulblishing Ltd 1991.
  9. Sophocles Am Jr. High altitude pulmonary edema in vail, Colorado, 1975-1982. West J Med 1986; 144: 569-73.
  10. Vock P, Fretz C, Franciolli M et al. High altitude pulmonary edema: findings at high-altitude chest radiography and physical examination. Radiology 1989; 170: 661-6.
  11. Krasney JA: A neurologic basis for acute altitude illness. Med Sci Sports Exerc 1994 Feb; 26(2): 195-208.
  12. Kasic JM, Nicholas RA, Roach R, et al. Treatment of acute mountain sickness: Hyperbaric versus oxygen therapy. Ann Emerg Med 1992; 20(10): 109-12.
  13. Coote JH. Medicine and mechanisms in altitude sickness. Sports Med, 1995; 20(3): 148-59.
  14. Grauer K, Cavallaro: ACLS a comprehensive review. Airplane emergencies 3rd ed. volume II, 1993: 465-6.
  15. Grover RF, Tucker CE, McGroarty SR, et al The coronary stress of skiing at high altitude. Arch Intern Med 1990; 150:1205-8.
  16. Tintinalli JE, Ruiz E, Krome RL: High altitude medical problems: Emergency medicine-A comprehensive study guide 4th ed. 1996; 873-880
  17. Auerbach PS: Aeromedical transport. Wilderness Medicine Management of Wilderness and Environmental Emergency 3rd ed.1995; 535-65.
  18. Auerbach PS: Wildness emergency medical services and response systems. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed.1995; 566-79.
  19. Malacrida RL, Anselmi LC, Genoni M, et al. Helicopter mountain rescue of patients with head injury and/or multiple injuries in southern Switzerland 1980-1990. Injury 1993;24:451-3.

¡@

¡@

¡@

¡@

¡@

§N¼ö«æ¯g

¥xÆW¦a³B¨È¼ö±a¦a°Ï¡A®L©u°ª·Å¥i¶W¹L37¢J¡A¥V©u§C·Å¥i§C¦Ü10¢J¥H¤U¡A¤s°Ï§ó±`¥i¨£0¢J¥H¤Uªº§C·Å¡A¹ï©ó¼ö«æ¯gÁöµL¥¿¦¡ªº²Î­p³ø§i¡A¦ý¦UÂå°|«o¸g±`¦³¹s¬Pªº³ø§i¡C¦Ó§CÅé·Å«oµLªk¦]³B©ó¨È¼ö±a¦a°Ï¦Ó­Æ§K¡A®Ú¾Ú³¯¦Û¥ß¤j¤Ò©ó1992¦~1¤ë¦Ü3¤ë¦b¥x¥_ºaÁ`©Ò°µªº²Î­p¡A´Nµo²{¤F23¦ìÅé·Å¤p©ó35¢Jªº§CÅé·Å«æ¶E¯f±w¡A¥i¨£¥xÆW¤´¦³¤£¤Ö§CÅé·Å¯f±w¡A­È±o¤j®aª`·N¡C1

¤HÅéÅé·Å½Õ¸`ªº¾÷Âà

¤@¯ë¦Ó¨¥¡A¤HÃþ¹ï¼öÀô¹Òªº¾AÀ³¡AÀu©ó§NÀô¹Ò¡A¦b´H§NÀô¹Ò¤¤¡A¥D­n»Ý¾a¬ïµÛ¾B½ªªº¦çª«¨Ó¨¾¤îÅé·Åªº´²¥¢¡C2¹ï©ó§N¡B¼ö«æ¯gªºµo¥Í¡A¥D­n¥Ñ¼ö¶qªº²£¥Í(¥]¬A¨­Åé²Ó­M¥NÁ©Ҳ£¥Íªº¥NÁ¼ö¤Î±q¥~¬ÉÀô¹Ò©ÒÀò±oªº¼ö¶q)»P¼ö¶qªº´²¥¢¨â­Ó¾÷Âà¨Ó¨M©w¡A·í¼ö²£¥Í¹L¦h©Î¼ö´²¥¢¤£¨}®É¡A§Y·|²£¥Í¼ö«æ¯g¡F¦p¼ö²£¥Í¤£¨¬©Î¼ö´²¥¢¹L¦h¡A«h·|²£¥Í§N«æ¯g¡C2,3

¼ö²£¥Í¾÷Âà

¨­Åé¼öªº²£¥Í¡A¤@¯ë¥i®Ú¾Ú¨Ó·½¡A¤À¬°¤º·½©Ê»P¥~·½©Ê¡A¦b¥¿±`ª¬ªp¤U¨­Å骺¼ö¶q¥i¥Ñ¤º·½©Êªº²Ó­M¥NÁ²£¥Í¡A©ÎªÌ¥~·½©Êªº±q¥~¬ÉÀô¹ÒÀò±o¡C¥¿±`ª¬ªp¤U¡C¤HÅ骺°ò¦¥NÁ¡A¨C¤p®É¬ù¥i¨Ï¨­Åé²£¥Í100¤j¥d(Kcal)ªº¼ö¶q©Î50-60¤j¥d/¤p®É/¥­¤è¤½¤ØÅéªí­±¿nªº¼ö¶q¡C4¦p¼ö¶q§¹¥þ¨S¦³´²¥¢¡A70¤j¤d¥dªº¼ö¶q«h±N·|¨ÏÅé­«70¤½¤çªÌ¡AÅé·Å¨C¤p®É¤W¤É0.8¢J¡F4¦p¦b¼@¯P¹B°Êªºª¬ªp¤U¡AÅé¼öªº²£¥Í¨C¤p®É«h¥i°ª¹F900¤d¥d¡F¦p¦b¤Ó¶§ª½±µ·Ó®gªºª¬ªp¤U¡A¨C¤p®É«h¤S¥i¼W¥[¼ö¯à¹F300¤d¥d¡C3¦]¦¹¡A¦p¦b¤j¤Ó¶§¤U°µ¼@¯P¹B°Ê¡A±N·|¨Ï¼ö²£¥Í¤j¶q¼W¥[¡A¦Ó¼W¥[¼ö«æ¯gªº¦MÀI¡C

¼ö´²¥¢¾÷Âà

¤HÅé¹ï©ó¼ö¶q´²¥¢¡A¥D­n¸g¥Ñ¤U¦C¥|ºØ¤è¦¡¨Ó½Õ¸`¡G3,4

  1. »]µo(evaporation)¡G¦½²G¸g¥Ñ»]µo¦ÓÅܬ°¤ô»]®ð¡A·í®ð·Å¶W¹L32¢J®É¡A¨­Åé¼ö¶qªº´²¥¢¡A³Ì¥D­n§Y¬O¾a¬y¦½¡A»]µo¤ô»]®ð¨Ó§¹¦¨¡A¦ô­p¨C»]µo1.7mlªº¦½¤ô¡A¥i´²µo1¤d¥dªºÅé¼ö¡CµM·íÀô¹Òªº¬Û¹ïÀã«×¶W¹L75%®É¡A»]µo´²¼öªº¯à¤O¡A§Yº¥º¥­°§C¡C
  2. ¿ç®g(radiation)¡G¼ö¤£¸g¥Ñ±µÄ²¡Aª½±µ¸g¹qºÏªi´²®g¨ìÀô¹Ò¤¤¡C¦b¤@¯ëª¬ªp¤U¡A·í¥~¬É·Å«×§C©óÅé·Å®É¡A65%ªºÅé¼ö³£¸g¥Ñ¿ç®g§@¥Î¨Ó´²¼ö¡A¨ä¤¤¤j³¡¥÷¥ÑÀY³¡¡]¬ù¦û50%¡^¡BÂù¤â¤Î¸}¨Ó´²¼ö¡C·íÀô¹Ò·Å«×¶W¹L32¢J®É¡A¨­Åé´X¥GµLªkÂÇ¿ç®g§@¥Î¨Ó´²¼ö¡C¦pÀô¹Ò·Å«×¶W¹LÅé·Å®É¡AÀô¹Òªº¼ö¤Ï¦Ó·|ÂÇ¿ç®g¶Ç¤JÅ餺¡A¦Ó¥i¯à¦¨¬°¨­Åé¦Û¥~¬ÉÀò±o¼ö¶qªº¥D­n¨Ó·½¡C
  3. ¶Ç¾É(conduction)¡GÅé¼ö¸g¥Ñª½±µ±µÄ²¦Ó´²¥¢¡A¤ôªº¶Ç¾É§@¥Î¤ñªÅ®ð§Ö240­¿¡C¦]¦¹¦p¬ïµÛÀã¦çªA¡A¼ö¶q±N·|§Ö³tªº´²¥¢¡C
  4. ¹ï¬y(convection)¡G¼ö¸g¥Ñ©P³òªÅ®ðªº¬y°Ê¦Ó´²¥¢¡A¦]¦¹¦b±j­·¤¤¡AÅé¼ö±N§Ö³t´²¥¢¡C

¡@

¡@

¼ö«æ¯g

·í¥ô¦ó¦]¯À¡AÅý¤HÅé³B©ó¤@­Ó¼ö²£¥Í¶W¹L¼ö±Æ°£³t«×®É¡AÅé·Å´N·|¤W¤É¡A¼ö«æ¯g´N·|²£¥Í¡C¤@¯ë¼ö²£¥Í¹L¦hªº±¡§Î¡A¥i¥H®Ú¾Ú²£¼ö¨Ó·½¤À¬°¤º·½©Ê¤Î¥~·½©Ê¡A¦p¼@¯P¹B°ÊÅýÅ餺²£¥Í¹L¦hªº¼ö¡A«hÄݩ󤺷½©Ê¼ö¹L¦h¡A¦p¦]©P³òÀô¹Ò®ð·Å«Ü°ª¡A¥~¼ö¶Ç¤JÅ餺¡A«hÄÝ©ó¥~·½©Ê¼ö¹L¦h¡C¦b¤@¯ëª¬ªp¤U¡A¨­Å鱯¼ö³Ì¥D­n¬O¾a¿ç®g¡]­ÉµÛ¦åºÞÂX±i¡A¼W¥[Åéªí¦å¬y¡A¦Ó¼W¥[¿ç®g¯à¤O¡C¦ý·í©P³òÀô¹Ò·Å«×¶W¹LÅé·Å®É¡A¨­Åé¦V¥~¿ç®gªº¯à¤O§Y®ø¥¢¡F¤Ï¦Ó¬O¥~¼ö¦V¤º¿ç®g¡A¦Ó¼W¥[¨­Å骺·Å«×¡^»P»]µo(±Æ¦½¡^¨â­Ó¾÷Âà¡A¦Ó³q±`¿ç®g¬O³Ì¥D­nªº±Æ¼ö¾÷Âà¡C¦ý·íÀô¹Òªº·Å«×³vº¥±µªñÅé·Å®É¡A»]µo«h¦¨¬°³Ì¥D­nªº±Æ¼ö¾÷Âà¡AµM¦Ó·íÀô¹ÒÀã«×¹L°ª®É¡A¨­Åé­É»]µo¨Ó´²¼öªº¯à¤O¤]±N³vº¥´î§C¡A¦¹®É«h¥²»Ý¾a¤@¨Ç¦æ¬°¡A¦p¥ð®§¡B§äÁ׳±³B(´î¤ÖÅé¼öªº¼W¥[) ¡B§j­·(¼W¥[¹ï¬y)¤Î§ä¤ô³Ü(¼W¥[Åé¼öªº´²¥¢) ¨Ó­°§CÅé¼ö¡C¤@¯ë¦Ó¨¥¡A¼ö¾AÀ³¨}¦nªº¤H¡A¨ä¥X¦½ªº³t«×¸û§Ö¡A¦½¤ô¤¤ªºÆQ¤À¸û§C¡A³q±`¸û¤£®e©öµo¥Í¼ö«æ¯g¡C¦¹¥~³\¦hÃĪ«(¦pªí¥|)¤Î¨­Åé¯e¯f(¦p¥Òª¬¸¢¥\¯à¤®¶i)¡A·|¼vÅT²£¼ö¤Î´²¼ö¡A¤]·|¥[­«¼ö«æ¯g¡C3,4

ªí¥|¡B¼vÅT·Å«×½Õ¸`ªºÃĪ«


¼W¥[²£¼öªºÃĪ«

Thyroid hormone

amphetamine

cocaine

Tricyclic antidepressants

Lysergic acid diethylamine (LSD)

´î§C¤f´÷¤ÏÀ³ªºÃĪ«

Haloperidol

§í¨î¥X¦½ªºÃĪ«

Antihistamines

Anticholinergics

Phenothiazines

Benztropine mesylate


¼ö«æ¯g¥D­n¥]¬A¤¤´»¡B¼ö°IºÜ¡B¼öµjÅ˵¥ª¬ªp¡AµM¤@¯ë»{¬°¡A¥¦­Ì¦³Ãþ¦üªºµo¥Í¾÷Âà¤Î¯f²zÅܤơA¥u¬OÄY­«µ{«×¤£¦P¦Ó¤w¡A¦]¦¹¡A¥i»¡¬O¼ö¹ï¨­Åé²£¥Í³sÄò©Ê´c¤Æªº¤£¦Pµ{«×ªí²{¦Ó¤w¡C3,4

¤@¯ë¦Ó¨¥¡A¤¤´»¬O¼ö«æ¯g¤¤³ÌÄY­«ªº¤@ºØ¡A¦¹®É¼ö²£¥Í¤w¤j¤j¦a¶W¹L¼ö´²µoªº¯à¤O¡A¨­Åé¤wµLªk¦³®Äªº´²µoÅé¼ö¡A¦]¦¹Åé·Å³q±`·|¤É±o«Ü°ª¡F¼ö°IºÜ«h¨­Åé³q±`¤´«O¦³³¡¤Àªº´²¼ö¯à¤O¡A¤´·¥¤O¥NÀv¥H´Á­°§CÅé·Å¡A¯f±w±`¦³ÄY­«ªº²æ¤ô²{¶H¡A¦ý·NÃѱ`¬O²M·¡ªº¡C

¡@

¤¤´»(heat stroke)

¤¤´»¬O¼ö«æ¯g¤¤³ÌÄY­«ªº¤@ºØ¡A¦º¤`²v¬Û·í°ª¡A¬ù¬°20-70%¡A±`¦b°ª·Å¡B°ª·Ã«×¡B¨S¦³­·ªºÀô¹Ò¤¤µo¥Í¡AÁ{§É¤W¶EÂ_¤¤´»±`¨Ì¾Ú1.¤¤¼Ï¯«¸g²§±`(¥]¬Aļ°Ê¡B°g½k¡B©âÝz¡B©ü°gµ¥)¡A2.ÄY­«°ªÅé·Å(¤¤¤ßÅé·Å>40.5¢J) ¡A3 .±Æ¦½¤£¨}¡Aµ¥¤T­Ó¥D­n¯g­Ô¡C¦Ó³o¤T­Ó¥D­n¯g­Ô¤¤¡A¨ä¹ê¯u¥¿¥u¦³¤¤¼Ï¯«¸g²§±`¡A¤~¬O¶EÂ_¤¤´»ªº°ß¤@¥²­n±ø¥ó¡A¦Ü©ó°ªÅé·Å¤Î¤£¥X¦½¡B°®Àꪺ¥Ö½§¡A¦b¤j®a¬Ý¨ì¯f±w®É¨Ã¤£¤@©w³£·|ªí²{¥X¨Ó¡C3,4,¥HÅé·Å¦Ó¨¥¡A®Ú¾Ú²Î­p¡A¤¤´»¯f±w¦b²{³õªº¥­§¡·Å«×¬°41.1¢J¡A¦Ó¦í°|®Éªº¥­§¡·Å«×«h¬°37.8¢J¡A¦]¦¹¯f±w¨ì¹F«æ¶E«Ç¡A¦pÅé·Å¨S¦³¹w´Áªº°ª¡A¤]¤£¯à§¹¥þ±Æ°£¤¤´»ªº¥i¯à¡C3¦¹¥~¡A¥H«e»{¬°¤£¥X¦½¡B°®Àꪺ¥Ö½§¬O¶EÂ_¤¤´»ªº¥²­n±ø¥ó¡A¦ý²{¦b¤]¤w¤£»{¬°¨º¬O¥²­n±ø¥ó¡A¦]³Ò°Ê«¬¤¤´»ªº¯f¤H¡A¬ù¦³¤@¥bªº¤H¤´·|Ä~Äò¥X¦½¡A°±¤î¥X¦½±`¬O¤¤´»ªº±ß´Á²{¶H¡A³q±`¦b¤¤´»ªº¦­´Á¡A¯f¤HÁÙ¬O·|Ä~Äò¥X¦½ªº¡C¥Ñ©ó¤¤´»ªº¯f¤H·NÃѤ£²M¡A±`µLªk±o¨ì¥¿½Tªº¯f¥v¡A©Ò¥H«Ü®e©ö©µ»~¶EÂ_¡AµM¦­´Á§Ö³t­°·Å«o¬O¨M©w¤¤´»¯f¤H¹w«áªº³ÌÃöÁä¦]¯À¡A¦]¦¹¦p¯à¦³EMT´£¨Ñ¨ì°|«eªº¯f¥v¡A±N¹ï¶EÂ_¦³«Ü¤jªºÀ°§U¡C3¤@¯ë¦Ó¨¥¡A¹ï©ó¤@¦ì·NÃѤ£²M¤S¦³°ªÅé·Åªº¯f±w¡A¦bŲ§O¶EÂ_®É¡AÀ³¥ý±Æ°£³o­Ó»Ý­n·m®É¶¡­°·Åªº¶EÂ_¡C

¨­Åé¾¹©xªº¯f²zÅܤơA¤@¯ë¦Ó¨¥¡A´X¥G©Ò¦³¾¹©x³£·|µo²{¦hµo©Êªº¥X¦å¡B¥R¦å(congestion)¤Î²Ó­M°h¤Æ(cellular degeneration)ªº²{¶H¡C³q±`¤p¸£¹ï¼öªº¶Ë®`¸û¬°±Ó·P¡A¦]¦¹¨BºA¤£Ã­±`¬O³Ì¦­¥X²{ªº¯gª¬¡C¸£³¡«h¥i¨£¨ì¸£¤ô¸~¡B¥X¦å¡B¥R¦åµ¥²{¶H¡CÁöµM¨S¦³¤@­Ó¯S©wÂ_µMªº·Å«×¡AÅã¥Ü¥X¤¤´»¦ó®É¶}©lµo¥Í¡A¦ý·í¤¤¤ßÅé·Å¹F42¢J®É¡A´X¥G¤j¸£³£¤£¥iÁ×§K¦a¤@©w·|¨ü¨ì¶Ë®`¡C3,4

¤@¯ë¥i®Ú¾Ú¤¤´»µo¥Í¾÷Âà¤Î­ì¦]¡A±N¤¤´»¤À¬°¶Ç²Î«¬(classic)»P³Ò°Ê«¬(exertional)¨âºØ(ªí¤­)¡C3,4,

  1. ¶Ç²Î«¬¤¤´»:¥D­nµo¥Í¾÷Âà¡A¬O¦]¼ö±Æ°£¤£¨}©Ò­P¡C1995¦~®L¤Ñ¡A¬ü°ê¼ö
  2. ®öŧ±²¡Aµ´¤j¦h¼Æ¯f±w¬OÄÝ©ó³o¤@ºØ«¬¤¤´»¡C¦hµo¥Í©ó¦Ñ¦~¤H

    ©Î¦³ºC©Ê¯e¯fªÌ¡A³o¨Ç¯f¤H¥i¯à¥u¦³°µ¤@¯ëªº¬¡°Ê¡A¦Ó¨S¦³°µ

    ¼@¯Pªº¹B°Ê¡A¨Ã±`¦bªA¥Î¤@¨Ç§í¨î±Æ¦½ªºÃĪ«©Î§Q§¿¾¯¡C

  3. ³Ò°Ê«¬¤¤´»:¥D­nµo¥Í¾÷Âà¡A¬O¤º·½©Êªº¼ö²£¥Í¹L¦h¶W¹L±Æ¼ö©Ò­P¡C¦hµo¥Í

©ó°·±dªº¦~»´¤H¡A¦b¼@¯Pªº³Ò°Ê©Î¹B°Ê(¦pªø³~¦æ­x)®Éµo¥Í¡C

¡@

¡@

ªí¤­¡B¶Ç²Î«¬¤Î³Ò°Ê«¬¤¤´»¤ñ¸û

¡@

¶Ç²Î«¬

³Ò°Ê«¬

¦~ÄÖ

¦Ñ¦~¤H

¦~»´¨k¤l(15-45·³)

°·±dª¬ªp

¦³ºC©Ê¯e¯f

°·±d¤H

¬¡°Ê

¤Ö

¼@¯P

¨Ï¥ÎÃĪ«

§Q§¿¾¯¡B¤TÀô§Ü§íÆ{¾¯¡B§Üºë¯«ÃĪ«¡B§Ü¤AñQÁxÆP¡B­°¦åÀ£ÃĪ«

³q±`µL

¥X¦½

¥i¯àµL

³q±`¦³

¥D­n¾÷Âà

´²¼ö¤£¨}

²£¼ö¹L¦h

¾î¯¾¦Ù¤À¸Ñ¯g

¤£±`¨£

±`«ÜÄY­«

¨Å»Ä¤¤¬r

³q±`µL

±`¨£

°ª¦å¹[

³q±`µL

±`¨£

§C¦å¶t

¤£±`¨£

±`¨£

§C¦å¿}

¤£±`¨£

±`¨£

CPK/aldolase

»´·L¤É°ª

ÄY­«¤É°ª

°ª§¿»Ä

»´«×

­««×

«æ©ÊµÇ°IºÜ

<5%

20-30%

DIC

»´«×

­««×

¡@

¤¤´»ªºªvÀø: ¤¤´»¬O¤@­Ó¦º¤`²v«Ü°ªªº¤º¬ì«æ¯g¡A¦Ó§Ö³t­°§CÅé·Å¡A«h¬OªvÀø¤¤´»¯f±w¡A§ïµ½¯f¤H¹w«áªº³Ì­«­n¡B³ÌÃöÁ䪺¦]¯À¡C3,4, 7,8

¤¤´»¤§²{³õ³B²z­ì«h¦p¤U: 2,3, 5,6,7,8

  1. Â÷¶}¼ö·½¡Aºû«ù©I§l¹D³qºZ¡Aµ¹¤©°ª¿@«×®ñ®ð¡C
  2. ¨³³t­°·Å¦Ü40¢J¥H¤U¡A¬O¨M©w¯f¤H¹w«áªº­«­nÃöÁä¡A¨ä¤èªk¥]¬A²æ±¼¦çªA¡B¼â§N¤ô¡A¦A¥Î­·®°§j¡A¥H¥[±j´²¼ö¡A¦¹¥~¥ç¥i¸m¦B³U©ó¤âÁu¡BµÅºÛ¡BÀV¡B½¥¥H¥[±j´²¼ö¡F¦b±ÏÅ@¨®¤º¡A±N§N®ð¶}¨ì³Ì¤j¡A¤]¬O¤@­Ó¦n¤èªk¡C
  3. ¥´¤WÂIºw(¥Î¥Í²z­¹ÆQ¤ô©ÎªL®æ¤ó²G) ¤@¯ë«ØÄ³¥H¨C¤p®É250¢Wªº³t«×µ¹¤©¡C
  4. ¥ß§Y°eÂå(§Y¨Ï¯f±wÅé·Å¤w¤U­°)¡C

¡@

¤¤´»¤§«æ¶E³B²z­ì«h¦p¤U: 2,3, 5,6,7,8

  1. ºû«ù©I§l¹D³qºZ¡Aµ¹¤©°ª¿@«×®ñ®ð¡A¥²­n®É¤©¥H©ñ¸m®ðºÞ´¡ºÞ¡C
  2. ¨³³t­°§CÅé·Å¡A¨Ã¨Ï¥ÎÅé·ÅºÊµø¾¹(©Î¥H¨z·Å­p©Î­¹¹D·Å«×­p¨C¤­¤ÀÄÁ´ú¶q¤@¦¸Åé·Å)¡C®Ú¾Ú³Ìªñ¬ã¨sÅã¥Ü¡A¼â§N¤ô(15¢J)¡B§j¹q®°ªº»]µo§N«o(evaporative cooling)¤è¦¡¡A­°·Å³t«×¥i¹F¨C¤ÀÄÁ0.31¢J¡F¦Óªw§N¤ôªº®ûªw§N«o(immersion cooling) ­°·Å³t«×«h¬°¨C¤ÀÄÁ0.15¢J¡C¥Ñ©ó®ûªw§N«o±`³y¦¨ÂåÅ@¤H­û³B²z¯f¤Hªº¤£«K¡B¯f±w·|¸û¤£µÎªA¡B®e©öµo§Ý¡B®e©öµo¥Í©âÝzªºª¬ªp¡A¦P®É»]µo§N«oªº­°·Å³t«×¤S¸û§Ö¡A¬G«ØÄ³Àu¥ý¨Ï¥Î»]µo§N«o¨ÓªvÀø¤¤´»¯f±w¡C¦Ü©óÅé·Å»Ý­°¨ì¤°»ò·Å«×¤~°±¤î©O?¥Ñ©óÅé·Å­°±o¤Ó§C¡A·|µo¥Í¤Ï¼u©Ê§CÅé·Å(Rebound hypothermia, or after drop) ¡A¤@¯ë«ØÄ³¯f¤HÅé·Å­°§C¦Ü38.5¢J®É¡A­°·Å´NÀ³°±¤î¡C
  3. ¸É¥R²GÅé¡A¨Ã©ñ¸m¤¤¤ßÀR¯ß¾ÉºÞ©ÎSwan-Gans¨Óµû¦ô¸É¥Rªº²G¶q¡C
  4. ©ñ¸m¾É§¿ºÞ¡A¨Ãºû«ù§¿¶q¨C¤p®É¨C¤½¤ç1ml¥H¤W¡C¥Ñ©ó¤¤´»¯f±w¬ù¦³25%·|µo¥Í«æ©ÊµÇ°IºÜ¡A¹ï©ó¤w¸É¥R¨¬°÷²GÅ骺¯f±w¡A¥iµ¹¤©manitol (0.25mg/kg) ¡Bfurosemide (1mg/kg)©ÎNaHCO3(1meq/kg)ªvÀø¡A¦p¦³¥²­n«h¦­´Á¤©¥H¬~µÇ¡C
  5. °lÂܦå²G±`³W¡B¾®¦å¥\¯à¡B¹q¸Ñ½è¡BµÇ¥\¯à¡B§¿²G±`³Wµ¥Àˬd¡C¤@¯ë¾®¦å¥\¯à²§±`¦h¦b18-36¤p®É¹F¨ì³Ì°ª®p¡ADIC(disseminated intravascular coagulation)¦h©ó24-72¤p®Éµo¥Í¡C
  6. Á×§K¨Ï¥Î£\-adrenergic(¦pnorepinephrine) ¡Banticholinergic(¦patropine) ¤Î¨ä¥L§í¨î¥X¦½ªºÃĪ«¡C
  7. Á×§K¨Ï¥Îaspirin¡Bacetaminophenµ¥¤@¯ë­°Åé·ÅªºÃĪ«¡C³o¨ÇÃĪ«¥D­n§@¥Î¦b¤Uµø¥Cªº·Å«×½Õ¸`¤¤¼Ï¡AµM¹ï©ó¤¤´»¯f±w¨ä¤Uµø¥C¨Ã¤£¹³¤@¯ë­P¯f·½(pyrogen)½Õ°ª¤FÅé·Åªº©w¦ìÂI¡A©Ò¥H¹ï©ó¤¤´»¯f±w³o¨Ç­n¬OµL®Äªº¡A¤Ï¦Ó·|¼W¥[°Æ§@¥Îªº²£¥Í¡A¦]¦¹¤£«ØÄ³¨Ï¥Î¡C
  8. ª`·NŲ§O¶EÂ_¡A¦Ò¼{¬O§_¦³¨ä¯e¯f¡A¦p·P¬V¡B¤º¤Àªc¯e¯f(¦phyperthyroidism©Îpheochromocytoma)µ¥ªº¥i¯à¡C

¡@

¡@

¼ö°IºÜ

¼ö°IºÜ¬O¤HÅé¦b°ª·ÅªºÀô¹Ò¤¤¤u§@©Î¹B°Ê¡A¬°¤F´²¼ö¦Ó±Æ¥X¤j¶qªº¦½²G¡A¦p¤ô¥÷¸É¥R¤£¨¬¡A±N³y¦¨²æ¤ôªº²{¶H¡C­Y²æ¤ô¹FÅé­«ªº2¢H¥H¤W®É¡A«h·|²£¥Í¼ö°IºÜªº¯gª¬¡C3,4,¯f¤H·|¦³ÀY·w¡Bµê®z¡Bäú¤ß¡B¹Ã¦R¡BÀYµh¡BÁy¦â»a¥Õ¡B¥Ö½§¥X¦½¡BÀã§N¡B¯ß·i§Ö¦Ó®z¡B«º¶Õ©Ê§C¦åÀ£¡B·w­Ë¡Bµø¤O¼Ò½kµ¥¯gª¬¡C¤@¯ëÅé·Å¥i¯à¥¿±`©Îµy°ª(¤p©ó40¢J)¡A¯f±w·NÃѳq±`²M¿ô¡C¦p¯f±w¦³·NÃѳॢ¡A¨Ã¦³«ùÄò°ª·Å«hÀ³¦Ò¼{¤w´c¤Æ¦Ü¤¤´»ªº¦a¨B¡C3,4

¼ö°IºÜ¤§²{³õ³B²z­ì«h¦p¤U: 3,4,5,6

1.Â÷¶}¼ö·½¡Aºû«ù©I§l¹D³qºZ¡Aµ¹¤©®ñ®ð¡C

2.¨ì³±²D³B¡AÅý¯f±w½ö¤U¡A¸}¹Ô°ª¡A¨Ã»P¥H­°·Å¡C

3.ÀR¯ßª`®g¥Í²z­¹ÆQ¤ô©ÎªL®æ¤ó²G¡C

4.¦p¯f±w·NÃѲM·¡¡A¥i¨C15¤ÀÄÁµ¹¤©¥bªM¤ô³Ü(¦p¹Ã¦R«hÁ×§Kµ¹¤©)¡C

  1. ¥ß§Y°eÂå¡C

¡@

¼ö°IºÜ¤§«æ¶E³B²z­ì«h: 3,4,5,6

  1. ­°§CÅé·Å(»P¤¤´»¬Û¦P) ¡C
  2. ¸É¥R²GÅé(±`»Ý§Ö³t¬I¤©1-2¤½¤Éªº¥Í²z­¹ÆQ¤ô©ÎªL®æ¤ó²G) ¡C
  3. ºû«ù¹q¸Ñ½è¥­¿Å¡A¨Ã¦¬¶°§¿²G¤ÎÅç¦å¡Aª`·N¬O§_µo¥Í¾î¯¾¦Ù¤À¸Ñ(rhabdomyolysis) ªº¥i¯à¡C
  4. ª`·N¬O§_¦³¨ä¥L¦X¨Ö¯gµo¥Í¡C

¡@

¼öµjÅË

¼öµjÅ˳q±`¬O¦b¼ö¤Ñ¼@¯P¹B°Ê«á¡A¸}³¡¦Ù¦×©Î¸¡³¡¦Ù¦×¬ðµMµo¥Í©âµ¬ªº¤@ºØ¯fª¬¡A¨ä­ì¦]³q±`¬O¦]¯f±w¦b¤j¶q¬y¦½¡A¬y¥¢¤ô¥÷¤ÎÆQ¥÷®É¡A¥u¦³³Ü¥Õ¶}¤ô©Î§C±i·»²G¡A¥H­PÆQ¥÷¸É¥R¤£¨¬©Ò­P¡C2

¼öµjÅ˲{³õªvÀø­ì«h¦p¤U: 3,4,5, 6,7,89

1.Â÷¶}¼ö·½¦Ü³±²D³B¡C

  1. Åý¯f±w¥ð®§¡C
  2. µ¹¯f±w³Ü¤ô©Î¥«°âªº¹B°Ê¶¼®Æ¡C

¡@

¼öµjÅË«æ¶EªvÀø­ì«h¦p¤U: 3,4,5, 6,7,8,9

  1. ¸É¥R²GÅé¡C
  2. ºû«ù¹q¸Ñ½è¥­¿Å¡A¨Ã¦¬¶°§¿²G¤ÎÅç¦å¡Aª`·N¬O§_µo¥Í¾î¯¾¦Ù¤À¸Ñªº¥i¯à¡C

¡@

¼ö¤ô¸~(heat edema)

³q±`¦bÃnÅS©ó¼öÀô¹Òªº«e´X¤Ñµo¥Í¡A¦hµo¥Í©ó¥¼¾AÀ³ªº¦Ñ¦~¤H¡A¤×¨ä¦b¸g¹L¤@¬qªø®É¶¡§¤¨T¨®¡B¤õ¨®©Î­¸¾÷ªº®È³~«á¡A§ó®e©öµo¥Í¡A°¸¦Ó­è±q§NÀô¹Ò®È¹C¦^¨Óªº¦~»´¤H¤]·|µo¥Í¡A¥¦³q±`µo¥Í©ó¤â©Î¸}¡A¸}½ï¥W³´©Ê¤ô¸~(pitting edema)°¸¦Ó¤]·|µo¥Í¡A¦ý³q±`¤£·|©µ¦ù¦Ü×H°©«eªº°Ï°ì¡A¨ä­ì¦]¥Ö½§¦åºÞÂX±i¤Î«º¶Õ©Ê²Õ´²G°±º¢©Ò­P¡A³q±`´X¤Ñ¤º·|¦ÛµM®ø¥¢¡A¤£¶·¯S§OªvÀø¡A¦ý¤´¥i¯à¿ð¦Ü6¶g¤~®ø¥¢¡A¦p¯f±w°í«ù­nªvÀø¡A¥i¥H¸}³¡©ï°ª¤Î¬ï¼u©ÊÄûªº¤è¦¡¡A¥HÀ°§U²Õ´²G¦^¬y¡C4

¡@

¡@

¼ö©ü³Ö(heat syncope)

³q±`¦b¼öÀô¹Ò¤¤¤[¯¸®Éµo¥Í¡A¨ä¥D­n­ì¦]¬°ÀR¯ß¦å²Gº¢¯d©ó¤UªÏ¤Î¬Û¹ïªº²GÅ餣¨¬¡A²£¥Í«º¶Õ©Ê§C¦åÀ£©Ò­P¡B¤@¯ë¥u­n±N¯f±w²¾¨ì³±²Dªº¦a¤è¡B½ö¥­¨Ãµ¹¤©¸É¥R¤ô¥÷³q±`¯gª¬«Ü§Ö·|®ø¥¢¡A¦ýÀ³ª`·N¬O§_¦³¤ßŦ¦åºÞ¡B¤¤¼Ï¯«¸g©Ê¯e¯fªº¥i¯à¡C3

¡@

¡@

§CÅé·Å

¤HÅ餤¤ßÅé·Å§C©ó36¢J´NºÙ°µ§CÅé·Å¡C¤@¯ë¨ÌÄY­««×ªº¤£¦P¡A¥i±N§CÅé·Å¤À¬°»´«×¡B¤¤«×¤Î­««×¡C¤¤¤ßÅé·Å34-36¢J¬°»´«×§CÅé·Å¡A30-34¢J¬°¤¤«×§CÅé·Å¡A30¢J¥H¤U¬°­««×§CÅé·Å¡C10¥Ñ©ó¤@¯ëÅé·Å­p³Ì§C¥u¯à¶q¨ì35¢J¡A¦]¦¹¥²¶·¨Ï¥Î¯S®íªºÅé·Å­p¡A(¦p¦Õ·Åºj¡B¨z·Å­p©Î­¹¹D·Å«×­pµ¥)¤~¯à¶q¨ì¸û§CªºÅé·Å¡C¤@¯ë¦pµL¯S®íªºÅé·Å­p¡A¥i¥Î¤â´x¸m©ó¯f±wªº¤W¸¡©Î«e¯Ý¡A­Y·Pı¦B§N®É¡A§YÀ³ÃhºÃ¦³§CÅé·Åªº¥i¯à©Ê¡C4¦¹¥~¡A¥ç¥i®Ú¾ÚÁ{§É¯gª¬¨Ó§PÂ_§CÅé·ÅªºÄY­««×(¦pªí¤»)¡C¤@¯ë¦Ó¨¥¡A¯f¤HªºÅé·Å­Y¦b32¢J¥H¤W¡A¨­Å餴«O¦³¹ï§Ü§C·Åªº¤ÏÀ³¡A·|¦³Å¸§Ý(¥H¼W¥[¼ö¯àªº»s³y) ¡B¤ß¸õ¥[§Ö¡B¦åÀ£¤É°ª¡B¥NÁ³t²v¼W¥[(¥H¼W¥[¨­Åé²£¼ö)µ¥¤ÏÀ³¡C·íÅé·Å­°¦Ü30-32¢J®É¡AŸ§Ý¯à¤O§Y®ø¥¢¡A¨­Å骺¥NÁ³t²v³vº¥´îºC¡A·|¦³¤ß¸õ´îºC¡A¦åÀ£­°§Cµ¥ªí²{¡C¦pÅé·Å§C©ó30¢J®É¡A¤ß¸õ·U¨Ó·UºC¡A¯ß·i³vº¥·L®z¦Ü´X¥G¤£©ö¹îı¡A¯f¤H¬Ý°_¨Ó´N¹³¦º¤H¤@¼Ë¡C3,10,11µM¦¹®É¤d¸U¤£¯à¦]¯f¤H¬Ý°_¨Ó¹³¦º¤H¦Ó»´©ö©ñ±ó«æ±Ï¡A¦]´¿¦³¤åÄmÅã¥Ü¡A¯f±w¦b15¢JªºÅé·Å¤U¡A¬Ý¦ü¦º¤`¡A¦ý¸g4­Ó¥b¤p®Éªº«æ±Ï«á¡A«o¤´¦³«ì´_ªº³ø§i¡C3

¦b¬ü°ê¡A¤j¦h¼Æ§CÅé·Å¯f±w³£»P°sºë¬ÛÃö3¡F¦Ó¦b¥xÆW¡A®Ú¾Ú³¯¦Û¥ßÂå®vµ¥ªº³ø§i¡A«h¥H§C¦å¿}¤Î±Ñ¦å¯g¬°³Ì¦h¡CµM¤@¯ë¦Ó¨¥¡A1¹ï©ó·Ä¤ô©Î¸ô­Ë¦h®Éªº¯f±w¡A³£À³ÃhºÃ¦³§CÅé·Åªº¥i¯à©Ê¡C

¹ï©ó§CÅé·Å¯f±w¤É·Åªº¤è¦¡¡A¤@¯ë¥i¤À¬°³Q°Ê¦^·Å¤Î¥D°Ê¦^·Å¡C¦Ó¥D°Ê¦^·Å¤S¥i¤À¬°¥D°ÊÅé¥~¦^·Å¤Î¥D°ÊÅ餺¦^·Å¡C3,10,11©Ò¿×³Q°Ê¦^·Å¡A§Y¬O«O·x¡AÁ×§K¼ö¶qÄ~Äò´²¥¢¡A¦ÓÅý¨­Åé¯à§Q¥Î¥»¨­¥NÁ©Ҳ£¥Íªº¼ö¯à¨Ó¤É·Å¡C¨ä¤èªk¥]¬A:1.¥h°£´H§Nªº¨Ó·½¡A±N¯f±w²¾¦Ü·Å·xªº¦a¤è¡C2.¥h°£Àã¦çª«¡A´«¤W°®ªº¦çªA¡C3.»\¤W¨¾­·¦çª«¡A¦p¤ò´àµ¥¡C10

¥D°ÊÅé¥~¦^·Åªº¤èªk¡A¥]¬A¨Ï¥Î¹q´à¡B¼ö¤ô³U¡B¯N¿O¤Îªw¼ö¤ô¯Dµ¥¡C10¥D°ÊÅ餺¦^·Åªº¤èªk«h¥]¬A¨Ï¥Î·ÅªºÀR¯ß¿é²G(43¢J) ¡B§l¤J·Å·x¼éÀ㪺®ñ®ð(42-46¢J)¥H¤Î¦UºØÅéµÄªºÄé¬~(lavage)¤É·Åªkµ¥¡C³q±`¦b¤£¦PªºÅé·Å¤U¡A§Ú­Ì¿ï¥Î¤£¦Pªº¤É·Å¤è¦¡¨ÓªvÀø¯f¤H(ªí¤C¡B¤K)¡C1

¡@

¡@

ªí¤»¡B§CÅé·ÅªºÁ{§Éªí²{

¢J

Á{§Éªí²{

37.6

¥¿±`ªº¨z·Å

37

¥¿±`ªº¤f·Å

36

¼W¥[¥NÁ²v¥H¹ï§Ü¥¢¼ö

35

¦b¦¹Åé·Å¡AŸ§Ýªº±¡§Î³ÌÄY­«

34

¯f¤H¦b¦¹Åé·Å¡A¤@¯ë¦³¤ÏÀ³¥B¦åÀ£¥¿±`

33

¤ß¹q¹Ï·|¥X²{Osborn(J) wave

32

Ÿ§Ý°±¤î¡B·NÃѤ£²M¡BÀû¤Õ´²¤j

31

¦åÀ£¤£©ö´ú±o

30

º¥¥¢¥h·NÃÑ¡A¦Ù¦×»øµw¼W¥[

29

¯ß·i¤Î©I§l´îºC¡A¥X²{¤ß«ß¤£¾ã

28

¦p¤ßŦ¨ü¨ì¨ë¿E¡A¥i²£¥Í¤ß«ÇÅÖºûŸ°Ê

27

¥¢¥h¦Û¥D°Ê§@¡A¤Î¥¢¥hÀû¤Õ¡B²`³¡¦Ù¸xµ¥¤Ï®g¡A¬Ý¨Ó¹³¤w¦º¤`

26

±wªÌ«Ü¤Ö¬O²M¿ôªº

25

¤ß«ÇÅÖºûŸ°Ê¥i¦Û°Êµo¥Í

24

¥iµo¥ÍªÍ¤ô¸~

22

¤ß«ÇÅÖºûŸ°Ê³Ì¥i¯àµo¥Í¦b¦¹·Å«×

20

¤ßŦ°±¤î¸õ°Ê

18

§CÅé·Å¯f±w¡A¥i«ì´_ªº³Ì§CÅé·Å

¡@

ªí¤C¡BªvÀø§CÅé·Åªº¤É·Å¤è¦¡

Åé·Å

¤É·Å¤è¦¡

»´«×Åé·Å(34-36¢J)

¡@

³Q°Ê¦^·Å

¥D°ÊÅé¥~¦^·Å

¤¤«×Åé·Å(30-34¢J)

¡@

³Q°Ê¦^·Å

¥D°ÊÅé¥~¦^·Å(¥u¥Î©óÂß·F)

­««×Åé·Å(<30¢J)

¡@

¥D°ÊÅ餺¦^·Å

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

ªí¤K¡BªvÀø§CÅé·Åªº¤É·Å¤èªk

¤É·Å¤è¦¡

¤É·Å¤èªk

³Q°Ê¦^·Å

¥h°£´H§Nªº¨Ó·½¡A±N¯f±w²¾¦Ü·Å·xªº¦a¤è¡C

¥h°£Àã¦çª«¡A´«¤W°®ªº¦çªA¡C

»\¤W¨¾­·¦çª«¡A¦p¤ò´àµ¥¡C

¥D°ÊÅé¥~¦^·Å

¹q´à

¼ö¤ô³U

¯N¿O

ªw¼ö¤ô¯D

¥D°ÊÅ餺¦^·Å

§l¤J·Å·x¼éÀ㪺®ñ®ð(42-46¢J)

ª`®g·ÅªºÀR¯ß¿é²G(43¢J¡A«ØÄ³µ¹¤©ªº³t«×¬°¨C¤p®É150-200 ml)

¸z­G¹D·Åªº²GÅéÄé¬~(¥]¬A¸z­G¤Î¤j¸zÄé¬~)

»H¯Ö·Åªº²GÅéÄé¬~

¸¡½¤·Åªº²GÅéÄé¬~(40-45¢J¡A¨Ï¥ÎµL¹[³zªR²G)

¦Ø½¤·Åªº²GÅéÄé¬~

Åé¥~´`Àô¤É·Å(extracorporeal rewarming)

Áa»JµÄ·Åªº²GÅéÄé¬~

¹ï©ó¦³¯ß·iªº¯f¤H¡A¤@¯ë«æ±Ïªº­«ÂI¡A©ñ¦b¦p¦ó¨ÏÅé·Å¦^´_¡A¨ä­ì«h¦pªí¤T¡B¥|¡C10ÁöµM³\¦h«æ±Ïªº³B¸m¡A¦p©ñ¸m®ðºÞ´¡ºÞ¡B»ó­GºÞ¡B¼È®É©Ê¤ßŦ¸`«ß¾¹¤ÎªÍ°Ê¯ß¾ÉºÞµ¥¡A¦pªG¾Þ§@®É°Ê§@²Ê¾|¡A®e©ö»¤µo¤ß«ÇÅÖºûŸ°Ê¡A¦ý¦p»Ý­n®É¤j®a¤]¤£À³¿ðºÃ³o¨Ç³B¸m¡A¤@¯ë¥u­n°Ê§@¤£­n¤Ó²Ê¾|¡A¤p¤ß©ñ¸m®ðºÞ´¡ºÞ¡A³q±`¬O¤£·|¼W¥[¤ß«ÇÅÖºûŸ°Êªºµo¥Í²v¡C10,11,12¹ï©ó§CÅé·Åªº¯f¤H¡A¦p¤@¶}©lºN¤£¨ì¯ß·i¡A»ÝÀˬd¯ß·i30-60¬í¡A¤~¯à½T©w¨ä¨S¦³¯ß·i¡C¥Ñ©ó¤ßŦ¦åºÞ¨t²Î¹ï©ó¹qÀ»¤Î«æ±ÏÃĪ«ªº¤ÏÀ³³£«Ü®t¡A¦pÅé·Å¦b30¢J¥H¤U¡A¹qÀ»3¦¸¤´µMµL®Ä®É¡AÀ³Ä~Äò§@CPR¡Aµ¥Åé·Å¦^¤É¦Ü30¢J¥H¤W¦A¶}©lµ¹ÃĤιqÀ»¡C10,11

§CÅé·Å¯f±wªº²{³õºò«æ³B²z­ì«h¦p¤U: 3,10,11

1.»´¬Xªº³B²z¯f¤H¡A¤ÅÅý¯f¤H¥Î¤O¡C

2.ºû«ù©I§l¹D³qºZ¡C

  1. ¦pµL©I§l¡A¥H¨C¤ÀÄÁ5¦Ü10¦¸ªº³t²vµ¹¤©¤H¤u©I§l¡A¦pµL¯ß·i(¯ß·iÀ³ÀË ¬d30-60¬í)µ¹¤©¤ßŦ«ö¼¯¡C

4.µ¹¤©·Å¼ö¼éÀ㪺100¢Hªº®ñ®ð(42-46¢J)¡C

5.¥i¤©¥H³Q°Ê¦^·Å¡C

6.¦p¥i¯à¡A¥i¤©¥HÀRª`®g·Å¼öªº¥Í²z­¹ÆQ¤ô(43¢J)¡C

  1. ¥ß§Y°eÂå¡C

¡@

§CÅé·Å¯f±wªº«æ¶E³B¸m­ì«h¦p¤U:,3, ,9,10,11,12

  1. ¦p¯f±w¦³¯ß·i¡A°£¤©¥H¤@¯ë°ò¥»ªº³B²z¦pABCµ¥¥~¡A¥i®Ú¾Ú¯f±wÅé·Åªº¤£¦P¡A¨Ï¥Î¤£¦PªºªvÀø¤è¦¡¡A¨ä­ì«h¦pªí¤T¡B¥|¡C¥Ñ©ó°ê¤º§CÅé·Å¯f±w±`¦X¨Ö§C¦å¿}©M±Ñ¦å¯g¡A¦]¦¹¡A§Ú­Ì¹ï©ó§CÅé·Åªº¯f±w¡A©yÀu¥ý·Q¨ì³o¨Ç¶EÂ_¨Ã§Ö³t¤©¥HªvÀø¡C¦b°ê¥~¡A¥Ñ©ó¤j¦h¼Æ§CÅé·Å¯f±w¦å¤¤°sºë¿@«×³£¤É°ª¡A¤@¯ë«ØÄ³¹ï§CÅé·Å¯f±w¥i¨Ò¦æ©Êµ¹¤©thiamine 100 mgÀR¯ßª`®g¡C¦bÂå°|¤¤¡A¦³®É¥Ñ©ó¿é¤J¤j¶q¥¼·Å¼öªº¦å²G©Î²GÅé¡A¤]·|¥X²{§CÅé·Åªº¯f±w¡A¤@¯ë¦pÅé·Å§C©ó33¢J¤ß¹q¹Ï§Y·|¥X²{©Ò¿×ªºOsborn(J) wave¡A§Y¦bQRSªi»PST segment¶¡¡A¥X²{¤@­Ó¬ð°_¦pÀd¾m®pªºªi§Î(¦p¹Ï)¡A³q±`Åé·Å¶V§C¡AJ wave·|§ó©úÅã¡C¦¹¥~¡A¦p¥Òª¬¸¢¤ÎµÇ¤W¸¢¥\¯à§C¤Uµ¥¤º¤Àªc¯e¯f¡A¤]®e©ö¦X¨Ö¦³§CÅé·Åªºªí²{¡A¤@¯ë«ØÄ³§CÅé·Åªº¯f±w¡A¦p¦X¨Ö¦³¥Òª¬¸¢¤ÎµÇ¤W¸¢¥\¯à§C¤Uªº¯f¥v¡AÀ³¦Ò¼{µ¹¤©hydrocortisone 100 mgÀR¯ßª`®gªvÀø¡CÁöµM¥u¦³«D±`¤Öªº§CÅé·Å¯f±w¦X¨Ö¥Òª¬¸¢¥\¯à§C¤U¡A¦ý¥Òª¬¸¢¥\¯à§C¤U¯f±w»P§CÅé·Å¯f±w¡A±`¦³«D±`¬Û¦üªºÁ{§Éªí²{¡A¦P®É¡Aµ´¤j¦h¼ÆªºÂH²G¤ô¸~©ü°g(myxedema coma)¯f±w³£·|§CÅé·ÅªºÁ{§Éªí²{¡A¦]¦¹¡A¤@¯ë«ØÄ³§CÅé·Åªº¯f±w¡A¦p¦X¨Ö¦³¥Òª¬¸¢¥\¯à§C¤Uªº¯f¥v¡BÀV³¡¦³¥Òª¬¸¢¤â³Nªº¬Í²ª©ÎÃhºÃ¦³ÂH²G¤ô¸~©ü°g®É¡AÀ³¤©¥H¥Òª¬¸¢²üº¸»XªvÀø¡C
  2. ¤@¯ë¦Ó¨¥¡A§CÅé·Åªº¤ßŦ¡A¹ï¤@¯ë§Ü¤ß«ß¤£¾ãªºªvÀø¦patropine¡B

    lidocaine¡B¤ßŦ¸`«ß¾¹¤Î¹qÀ»µ¥³q±`¤ÏÀ³³£¸û®t¡A¥Ø«e°ß¤@¹ï§CÅé·Åªº¤ßŦ¦³

    ®ÄªºÃĪ«¬Obretylium toslyate¡AÁöµM¦³¨Ç¤ß«ß¤£¾ã·|«Â¯Ù¨ì§CÅé·Å¯f±wªº¥Í©R

    ¦w¥þ¡AµM¹ï©ó§CÅé·Å¯f±w¡A¤j¦h¼Æªº¤ß«ß¤£¾ã¦pÄu©Ê¤ß·i¹LºC¡B¤ß©ÐÅÖºûŸ°Ê¡B

    ¤ß©Ð¼³°Êµ¥¡A³q±`¦bÅé·Å¦^¤É«á¡A·|¦ÛµM«ì´_¡A¦]¦¹¡A¦b§CÅé·Å®É³q±`¤£»Ý­nªv

    Àø¡C10

  3. ¦p¯f±wµL¯ß·i(À³Àˬd30-60¬í) ¡A«hµ¹¤©¤ßŦ«ö¼¯¡C¦p¦¹®É¯f±wÅé·Å¦b30¢J¥H¤U¡A­ì«h¤WÃĪ«¼È®É¤£µ¹¤©¡A¤@¯ëµ¥Åé·Å¦^¤É¨ì30¢J¥H¤W®É¡A¦Aµ¹¤©«æ±ÏÃĪ«¡C¦p¯f±wÅé·Å¦b30¢J¥H¤U¡A¤ß¹q¹Ï¥X²{¤ß«ÇÅÖºûŸ°Ê©Î¤ß«Ç¤ß«ß¹L³t(VF/VT) ¡A¥i¥ýµ¹¤©¯f±w¹qÀ»¤T¦¸¡A¦p¤´¨S¦³«ì´_¡A«h¤£Ä~Äòµ¹¤©¹qÀ»¡Aµ¥Åé·Å¦^¤É¨ì30¢J¥H¤W¡A¦A¦p¤@¯ëACLSªº¬yµ{µ¹¤©ªvÀø¡C¦p¯f±wÅé·Å¦b30¢J¥H¤W¡A«hªvÀø§Y¨Ì·Ó¤@¯ëACLSªº¬yµ{µ¹¤©ªvÀø§Y¥i¡A°ßÃĪ«µ¹¤©ªº¶¡¹j®É¶¡¡A¤@¯ë«ØÄ³¥H¸ûªøªº®É¶¡¶¡¹jµ¹¤©¡C10

¹ï©ó¤ß¹q¹Ï¥X²{¤ß«ß°±¤î(asystole)ªº¯f±w¡A¥Ñ©ó§Nªº¥Ö½§¹ï¹qªº¶Ç¾É¤£

¨}¡A§Y¨Ï¯f±w¤ß«ß¤£¬Oasystole¡A¤]¥i¯à¦]¥Ö½§¾É¹q¤£¨}µLªk¶Ç¹F¤ß¹q¦Ü¤ß¹q

¹Ï¤W¡A¦ÓÅã¥Üasystole¡A¦¹®É¥i¦b¾Éµ{(lead)¶K¤ù¤W¡A¥Î°wÀYª½±µ´¡¤J¥Ö¤U

(needle electrodes) ¡A¥H¥[±j¾É¹q«×¡A³o®É¦p¤ß¹q¹Ïªi§Î§ïÅܤF¡A¦A®Ú¾Ú§ïÅÜ

ªº¤ß¹q¹Ï¤Î¯f±wªºÅé·Å°µ¤£¦PªºªvÀø¡C10,11

¡@

§½³¡§N¶Ë®`

§½³¡§N¶Ë®`¡A¥i¤À¦B­á(freezing)¤Î«D¦B­á¶Ë®`(nonfreezing)¶Ë®`¡C¦B­á¶Ë®`«ü¨­Åé§½³¡²Õ´³B©ó0¢J¥H¤U¡A¤ô¦b²Ó­M²Õ´¤ºµ²¦¨¦B¶ô¡A¦Ó³y¦¨¶Ë®`[¦p­á½H(frostbite)] ¡C«D¦B­á¶Ë®`«h«ü¨­Åé§½³¡²Õ´ªø®É¶¡ÃnÅS©ó0¢J¥H¤Wªº§C·ÅÀô¹Ò¡A©Ò³y¦¨¶Ë®`¡A¥¦¤S¥i¤À¬°°®§NÀô¹Ò[¦p­á»ø(chilblain)¤Î·Ã§NÀô¹Ò[¦p¾ÔÀ¢¨¬(trench foot)]©Ò²£¥Íªº¶Ë®`¡C3,11,13

¡@

¡@

¡@

¦B­á¶Ë®`

­á½H(frostbite)

­á½H¡A±`¦ñÀH¦³§CÅé·Å¦P®É¦s¦b¡A§Î¦¨ªº­ì¦]¦b©ó¨­Åé§½³¡²Õ´³B©ó0¢J¥H¤U¡A¤ô¦b²Ó­M²Õ´¤ºµ²¦¨¦B¶ô¡A¨Ã³y¦¨¤p¦åºÞªºªý¶ë¦Ó²£¥Í¡A¥Ñ©ó¦B­áªºªÏÅé¦b¸Ñ­á«e«Ü¤£®e©ö§PÂ_¨ä½T¹êªºÄY­««×¡A¦]¦¹¹ï©ó­á½Hªº¤ÀÃþ±`¨Ï¥ÎªÏÅé¦^·Å(remarming)®Éªºª¬ªp¨Ó¤ÀÃþ¡A¤@¯ë¥i¤À¬°¥|«×: 2,3,9,10

²Ä¤@«×:¦A·x©M«á¥Ö½§ªx¬õ¡B¥R¦å¡B¦³»´«×¤ô¸~¡A¦ý¨S¦³¤ôªw¡A¤]¨S¦³Ãa¦º¡A·|¦³

Äo¡B¨`¼ö¤Î¸~µÈªº·Pı¡C

²Ä¤G«×:¦A·x©M«á¥i¨£¤ôªw§Î¦¨¡A¤ôªw¤º²GÅé¼á²M§e½_¯ó¦â¡A¥Ö½§ªx¬õ¡B¥R¦å¡B¦³

©úÅ㪺¸~µÈ¡A·|¦³±j¯P¿N¨`ªº·Pı¡A³q±`¦X¨Ö³¡¤À«p«×ªº¥Ö½§Ãa¦º

(partial thickness necrosis) ¡C

²Ä¤T«×:¦A·x©M«á¥i¨£¥X¦å©Ê¤ôªw¡A¥Ö½§ÃC¦â§e¦Ç¦â¡A¯f±w·|¦³¤ì¤ìªº·Pı¡A³q

±`¦X¨Ö¥þ«p«×ªº¥Ö½§Ãa¦º(full thickness necrosis) ¡A¨Ã¥i«I¥Ç¨ì¤@¨Ç¥Ö¤U

²Õ´¡C

²Ä¥|«×:¦³¥þ«p«×ªº¥Ö½§Ãa¦º¡A¨Ã¦X¨Ö¤j¶q¥Ö¤U¦Ù¦×¡B°©Àf¡B¦Ù¸xªº¦º¤`¤ÎÃa³I¡A

¥Ö½§ÃC¦âµoÖæ¡A¥Î¤â«üÀ£µoÖæªº³¡¤À¨Ã¤£·|ªx¥Õ(nonblanching

cyanosis) ¡A¥Ö½§¥i¦³¤pªº¥X¦å©Ê¤ôªw¡A·Pı¦h¥b®ø¥¢¡A¦ý¥i¦³²`³¡Ãö¸`

¯kµhªº·Pı¡C

²{³õ³B²z­ì«h: 3,10

  1. ²¾Â÷´H§NÀô¹Ò¡A¨Ã°£¥hÀ㪺¦çª«¡B¾c¡BÄû¡C
  2. À³ª`·N¬O§_¦³¦X¨Ö§CÅé·Å©Î²æ¤ôªº¥i¯à¡A¥iµ¹¯f¤H³Ü¼ö¤ô¡C
  3. ªw·Å¤ô(40-42oC)§Ö³t¦^·Å¡A¬OªvÀø­á½H³Ì¦³®Äªº¤èªk¡AµMÀ³Á×§K°®¼ö¦^·Å(¦p¤õ¯N,¦]·|¨Ï¨ü¶Ëªº²Õ´¹L©ó°®Àê¨Ã¼W¥[¿S¶Ëªº¦MÀI) ¡C¥Ñ©ó¸Ñ­á«á¦A¦B­á¡A·|¼W¥[²Õ´¶Ë®`ªºÄY­««×¡A¦p¹w´Á¯f±w¦b¹B°e³~¤¤ªÏÅéÁÙ·|¦A¦B­á(¦p¯f±w»Ý¾a¦Û¤v¨«¤U¤s) ¡A«h¼È®ÉÀ³¥ý¤£­n±N¦B­áªºªÏÅé¸Ñ­á¡C
  4. ¾¨³t°eÂå¡C

¡@

«æ¶E³B²z­ì«h: 3,,12,14,15

  1. °£¥hÀ㪺¦çª«¡B¾c¡BÄû¡Aª`·N¬O§_¦³¦X¨Ö§CÅé·Å©Î²æ¤ôªº¥i¯à¡A¨Ã¦Ò¼{¤©¥H¥þ¨­©Ê¤É·Å©Î¸É¥R¤ô¥÷¡C
  2. ªw·Å¤ô(40-42oC)§Ö³t¦^·Å¡Aª½¨ìªÏÅéªx¬õ©ÎÅܬX³n¡C
  3. ¹ï©ó¤ôªwªº³B²z¡A¥Ø«eÁö¦³¤£¦Pªº¬Ýªk¡A¦ý¤@¯ë¦P·N¹ï©ó²M²Gªº¤ôªw¥i©â§l¤ôªw²G©Î¤©¥HÂX³Ð(¦]¤ôªw²G¤º´I§t¹ï²Õ´¦³¯}Ãa©Êªºprostaglandin¤Îthromboxane) ¡F¦ý¹ï©ó¥X¦å©Ê¤ôªw¡A¤@¯ë«h«ØÄ³¤£­n§Ë¯}¡A¤]¤£­n©â¨ú¤ôªw¤º²GÅé(¦]·|¨Ï¨ä¤U¤èªº²Õ´¹L©ó°®Àê¡A¨Ã¨Ï¹w«á§óÁV)¡C
  4. ¥Ñ©ó­á½Hªº¶Ë¤f¡A¬OÄÝ©ó®e©ö±o¯}¶Ë­·(tetanus-prone)ªº¶Ë¤f¡AÀ³¨Ì·Ó©ö±o¯}¶Ë­·¶Ë¤fªº¹w¨¾­ì«h¡Aµ¹¤©¯f±wÃþ¬r¯À(tetanus toxoid)©Î§K¬Ì²y³J¥Õ(tetanus immune globulin) ¡C
  5. ¥i§½³¡µ¹¤©aloe vera (dermaid aloe cream)©Î¤fªA¨C¤Ñ12mg/kgªºibuprofen (mortrin)¥H§í¨îarachidonic acidÂàÅܦ¨¹ï²Õ´¦³¶Ë®`ªºprostagladin©Î thromboxane (¸garachidonic acid¸ô®|ÂàÅܦ¨prostagladin or thromboxane¡A·|«P¶i¦åºÞ¦¬ÁY¡B¦å¤pªO¾®¶°¡A¦Ó¥[­«°ÊÀR¯ß®ê¶ë¡A¨Ã¨Ï±o¯Ê¦å¡BÃa¦º¡BÃa¯j§ó¬°ÄY­«) ¡C
  6. µ¹¤©§Ü¥Í¯ÀªvÀø¡A¤@¯ë«ØÄ³¨C¤»¤p®Éµ¹¤©ÀR¯ßª`®g500,000³æ¦ìªºpenicillin G(¦]³Ì±`¨£ªº·P¬V¯f·½µß¬°Staphylococcus aureus, Staphylococcus epidermilis¦ýanaerobes, Pseudomonas, ¤ÎEnterococcus¤]¬O­«­nªº¯f·½µß) ¡C§½³¡¨Ï¥Îbacitracin§Ü¥Í¯ÀÃÄ»I¡A´¿¦³³ø§iÅã¥Ü¦³§U©ó·P¬Vªº¹w¨¾¡A¦ý§½³¡¨Ï¥Îsilver sulfadiazine (Silvadene)§Ü¥Í¯ÀÃÄ»I¡A«h¨Ã¥¼Åã¥Ü¹ê½èªº§Q¯q¡C
  7. ¤Å¤Ó¦­¨Ï¥Î¥~¬ìÂX³Ð³N(¤Ó¦­¨Ï¥Î¥~¬ìÂX³Ð³N¡A±`¬O³y¦¨¤£¥²­n²Õ´·l¥¢ªº¥D¦]¡A¦n¡BÃa²Õ´ªº¬É­±¡A³q±`»Ý3-4¶g¤~·|§¹¥þ©úÅã¡A¦]¦¹¤@¯ë«ØÄ³ºIªÏ©Î¸É¥Ö¡A¦b¦¹®É¹ê¬I¸û¨Î) ¡C

¡@

«D¦B­á¶Ë®`

­á»ø(chilblain)

ªÏÅéªø®É¶¡ÃnÅS©ó0oC¥H¤W§C·Å°®ªºÀô¹Ò¤¤¦Ó²£¥Í¡A¤@¯ëµn¤sªº¤s©Î¤Í¤k©Ê¸û®e©öµo¥Í¡A¤×¨ä·í¯f±w¦³¹p¿Õ(Rayround phenomenon)®É§ó®e©öµo¥Í¡A¦nµo©ó¤â¡B¸}¤Î¦Õµ¥³¡¦ì¡A¦h¼vÅT¥Ö½§ªºªí¼h¡C11³q±`¦bÃnÅS§C·ÅÀô¹Ò12¤p®É«áµo¥Í¡Aªì´ÁªÏÅé·|µo¥Õ¡AµM«á·|¥X²{§½³¡¤ô¸~¡Bµo¬õ¡BµoÖæ¡A¨Ã¥i§Î¦¨µw¶ô¡A·|²£¥ÍÄo¡B¿N¨`¤Î³Â¤ìªº·Pı¡C3

¡@

¾ÔÀ¢¨¬(trench foot)

¾ÔÀ¢¨¬¬O¦]¸}ªø®É¶¡ÃnÅS©ó0oC¥H¤W§C·Å·ÃªºÀô¹Ò¤¤¦Ó²£¥Í¡AÅU¦W«ä¸q¡A¥H«e¥¦±`µo¥Í©ó¤h§Lªø®É¶¡¯¸¦b¦³¤ôªº¾ÔÀ¢¤¤¦Ó²£¥Í¡C³q±`ªì´Á²Õ´ªº¶Ë®`¦h¬°¥i°fªº¡A¦ý¦pÃnÅS®É¶¡¤Óªø¡A¥ç¥i²£¥Í¥Ã¤[ªº¶Ë®`¡C¤@¯ë¯¸¦b·ÃªºÀ¢·¾¤¤¼Æ¤p®É§Y¥iµo¥Í¡Aªì´ÁªÏÅé·|¦³»a¥Õ¡B»øµw¡B´³»éª¬¤Î¯ß·i·L®zªº²{¶H¡A¨Ã¦³³Â¤ìªº·Pı¡A´X­Ó¤p®É«áªÏÅé·|¥R¦å¡A·|¦³¨`µhªº·Pı¡A2-3¤Ñ«á¥ç¥i§Î¦¨¤ôªw¡C3,15

«D¦B­á§N¶Ë®`ºò«æ³B²z­ì«h: 3,15,

  1. ²¾Â÷´H§NÀô¹Ò¡A°£¥hÀ㪺¦çª«¡B¾c¡BÄû¡C
  2. ªw·Å¤ô(40oC)ª½¨ìªÏÅé«ì´_´`ÀôÃC¦âÅܬõ(³q±`20-30¤ÀÄÁ) ¡AÁ×§K°®¼ö¡C
  3. ¥iµ¹¤©nifedipine 20 mg t.i.d.(¥ç¥i¥Î©ó¹w¨¾) ¡C
  4. ´¿¦³³ø§iÅã¥Ü§½³¡¨Ï¥Î©Î¤fªAÃþ©T¾J¦³®Ä¡A¥i¦Ò¼{¨Ï¥Î¡C

¡@

¡@

¡@

¡@

¡@

¡@

¡@

¡@

°Ñ¦Ò¸ê®Æ:

  1. ³¯¦Û¥ß¡B­J³Ó¤t¡B§ù·ç·×µ¥: «æ¶E¯f¤HÅé·Å¹L§C¤§±´°Q¡C¤¤µØÂå»x, 1993; 52:425-30.
  2. Crawshaw LI, Auerbach PS: Thermoregulation Wilderness Medicine- Management of

Wilderness and Environmental Emergency 3rd ed.1995; 38-50

  1. Tintinalli JE, Ruiz E, Krome RL: Frostbite and other localized cold-related injuries, hypothermia, heat emergency: Emergency medicine-A comprehensive study guide 4th ed. 1996; 843-856.
  2. Hubbard RW, Gaffin SL, and Squire DL. Heat-related illness . Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed.1995;167-212.
  3. Thein LA: Environmental conditions affecting the athelete: Journal of Orthopaedic and Sport Physical Therapy. 1995; 21(3): 158-71.
  4. Tom PA. Garmel GM, Auerbach PS: Environment-dependent sport emergencies. Medical Clinics of North America.1994;78(2): 305-25.
  5. Harker J. Gibson P: Heat-stroke: A review of rapid cooling techniques. Intensive & Critical Care Nursing. 1995;11(4): 198-202.
  6. Lee-Chiong TL and Stitt JT. Heatstroke and other heat related-illnesses. Postgraduate medicine. 1995; 98(1):26-36.
  7. Clarkson PM and Miles MP. Exercise-induced muscle pain, soreness, and cramps. The Journal of Sport Medicine and Physical Fitness. 1994, 34(3): 203-14.
  8. Cummins RO and subcommittee on advanced cardiac life support, American Heart Association: Special resuscitation Situations. Textbook of Advanced Cardiac Life Support. 1997; 11-1¡X11-19
  9. Danzl DF, Pozos RS, Hamlet MP. Accidental Hypothermia. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed.1995; 51-103.
  10. Antretter H. Dapunt OE. Bonatti J.: Management of profound hypothermia. British Journal of Hospital Medicine. 54(5): 215-20, 1995 Sep 6-19.
  11. Committee on Trauma, American College of Surgeons: Injuries due to burns and cold. Advanced trauma life support. Sixth edition, 1997; 273-288.
  12. MaCauley RL, Smith DJ, Robson MC, et al. Frostbite and other cold-induced injuries. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed.1995;129-45.
  13. Lee-Chiong TL Jr. Stitt JT: Accidental hypothermia. Postgraduate Medicine. 99(1): 77-80, 83-4, 87-8, 1996 Jan.

¡@

,.

¡@

¡@

¡@

»P¤ô¦³Ãöªº«æ¯g

·Ä¤ô

¥xÆW¥|­±Àô®ü¡A¨C¦~·Ä¦ºªº¤H³£¦b¤d¤H¥H¤W¡A¥B¦ºªÌ¦h¥H¦~»´¤H¬°¥D¡A¹ïªÀ·|¸ê·½·l¥¢«Ü¤j¡A¦]¦¹¦b°ê¤º¬O¤@­Ó«D±`­«­nªº½ÒÃD¡C¦Ó·Ä¤ô¯f¤Hªº¹w«á¡A³Ì­«­n§Y¨ú¨M©ó¶}©l±Ï´©ªº®É¶¡¡A¦]¦¹ºò«æÂåÀø±ÏÅ@¨t²Îªº¦nÃa¡A§Y¬O¨M©w·Ä¤ô¯f¤H¹w«áªº³Ì­«­n¦]¯À¡C1

·Ä¤ô¯f±w¥D­n¬O¦]²¿®§¯Ê®ñ¦Ó¦º¤`¡A¦]¦¹¦bªvÀø®É¯S§O¶·µ¹¤©°ª¿@«×®ñ®ðªº¡C1,2Ãö©ó·Ä¤ôªº©w¸q¡A¦U¬É¤´¦³¤£¦Pªº¬Ýªk¡A´¿¸g¦³¤H±N·Ä¤ô(near-drowning)©w¸q¬°¯f±w¨I©ó¤ô¤¤´Xªñ²¿®§«á¡A¦Ü¤Ö´¿¸g¼È®É¦s¬¡¹L(´¿¸g¦³¯ß·i¹L)¡F¦Ó·ÄÀÅ(drowning)«h¬O«ü¨I©ó¤ô¤¤²¿®§«á³y¦¨¦º¤`(¥¼´¿«ì´_¹L¯ß·i)¡C¦ý¦b²{³õ¤@¯ë¬OµLªk¤À§O¡A¤]µLªk¨M©w¯f±w·|¤£·|¦s¬¡¡C¦]¦¹¡A¥Ø«e¤@¯ë±N·Ä¤ô©w¸q¬°¨I©ó¤ô¤¤ªº¯f±w¬¡¹L24¤p®ÉªÌºÙ¤§¡F¦Ó·ÄÀÅ«h«ü¥¼¬¡¹L24¤p®ÉªÌ¡C1,2,3,4¦¸µo©Ê·Ä¤ô(secondary drowning)¬O«ü¯f±wµo¥Í©µ¿ð©ÊªÍ¤ô¸~¦Ó¦º¤`¡C1,2,3®û¤ô¯g­Ô¸s(Immersion syndrome) «h«ü¯f±w¨I©ó¤ô¤¤¡A¥Ñ©ó°g¨«¯«¸gªº¹L«×¨ë¿E¡A¦Ó³y¦¨¤ßŦ°±¤î¡C1,2,3

®Ú¾Ú²Î­p¡A·Ä¤ô¦º¤`ªº¯f±w¡A¤j¬ù¦³10-12%ªº¦ºªÌ¨S¦³©úÅ㪺¤ô¶i¤JªÍ¤º¡A¦¹§Y©Ò¿×ªº¡¨°®·Ä¡¨(dry drowning) ¡A3,5¨ä­ì¦]¥D­n¬O«|³¡¦Ù¦×µjÅË¡AªýÂ_¤F¤ô¶i¤JªÍ³¡©Ò­P¡F1,2,3,5¦Ó¥t¥~ªº85-90%ªº¯f±w¡A«h¦³©úÅ㪺¤ô¶i¤JªÍ³¡¡A¦¹§Y¬°©Ò¿×ªº¡¨Àã·Ä¡¨(wet drowning)¡C1,2,3¤@¯ëÀã·Äªº¯f¤H¡A¥u¦³¤¤µ¥¶qªº¤ô¥÷¶i¤JªÍ³¡¡A¦b¹ï·Ä¤ô¯f±w«æ±Ï®É¡A¥H«e´¿¹Á¸Õ±NªÍ¤¤ªº¤ô¤Þ¬y¥X¨Ó¡A²{¦b»{¬°¬O¤£¥²­nªº¡A´¿¦³¬ã¨sÅã¥Ü¡A¯u¥¿¯à¤Þ¬y¥XªÍ¸Ìªº¤ô±N¤£¨ì1%¡A99%ªºªÍ¸Ìªº¤ô§Ú­ÌÁÙ¬OÀ½¤£¥X¨Ó¡A¦Ó¥B±q«e©Ò¥Îªº«º¶Õ©Ê¤Þ¬y©Î«¢©i¥ß§J«æ±Ïªk(Heimlich maneuver)¡A¨Æ¹ê¤W³£¤£·|¼W¥[¯f±wªº±Ï¬¡²v¡C¦P®É¡A§A©ÒÀ½¥X­G¸Ìªº¤ô¡A¤Ï¦Ó·|¼W¥[ªÍ§l¤Jªº¦MÀI¡A¨Ã¥B°µ³o¨Ç°Ê§@ÁÙ·|©µ»~µ¹®ñ¤Î©I§lªº®É¶¡¡C1,2,3,5,6¦]¦¹¡A¥Ø«e¹ï©ó¤@¯ëªº·Ä¤ô¡A°£«D¯f±w½T¹êÃhºÃ¦³©I§l¹Dªý¶ë¡A©Î¯f±w¤w©ñ¸m¤F®ðºÞ´¡ºÞ«á¦]¸¡³¡¤ÓµÈ¼vÅT¨ì©I§l(¦¹®É¥i©ñ­GºÞ¤Þ¬y­G¤¤ªº¤ô)¡A§_«h¨S¦³¥²­n¨Ï¥Î«¢©i¥ß§J«æ±Ïªk©Î¨ä¥Lªº¤èªk¤Þ¬yªÍ¤¤ªº¤ô¡C¥u­n¦p¤@¯ë°µCPR§Y¥i¡C1,2,3,5,6

·Ä¤ô¯f±wªº±Ï´©2,7,8

¹ï·Ä¤ô¯f±wªº±Ï´©¤§«e¡AÀ³¥ý½T©w±Ï´©ªÌªº¦w¥þ¡A¤£­nÅý¦Û­n¤]¦¨¬°¤@­Ó¨üÃøªÌ¡C³\¦h¤ô¤¤·N¥~¡A¶Ë±w¬O¥HÁy´Â´Â¤Uªº«º¶Õº}¯B¡A¦]¦¹§A¥²¶·±N¥L½Âà¹L¨Ó¡A¨Ï¥L¦¨¬°­I³¡´Â¤U¡A½Â઺­ì«h¦p¤U¡G

  1. ¨ÏÀY¤Î¨­Âߦ¨¤@ª½½u¡C
  2. ¤@¤â¸m©ó¶ËªÌ­I³¡¤¤¶¡¡A¥t¤@¤â¸m©ó¶ËªÌ¤UÃE©Î¤WÁu¾aªñªÓ»H³B¡C
  3. ©ó¤ô¤¤Â½Âà¯f±w¡Aºû«ùÀY¤Î¨­Âߦ¨¤@ª½½u¡C
  4. ±N±Ï¥Í¾¹¨ã²¾¦Ü¯f±w¨­®Ç¡C
  5. ±N¯f±w©T©w«á¡A·h²¾¥X¤ô¡C

¤@¯ë¦b¤ô¤¤CPR¬OµL®Ä¡A¥B¹ï±Ï¥Í¤H­û¬O«D±`¦MÀIªº¡A¦]¦¹¡A°£«D±Ï¥Í¤H­û¤w¨ü¹L«D±`§¹³Æªº°V½m¡A¥B¦³¤@­Ó°íµwí¦]ªºªí­±¡A§_«h¤£­n»´©ö¨Ï¥Î ¡C

¡@

¡@

¡@

¹ï©óÃhºÃ¯á´Õ¨ü¶Ëªº±wªÌ¡A±Ï´©¤H­û«OÅ@¯á´Õ¡AÀ³ª`·N¥H¤U¥|­Ó­ì«h

  1. ¤Å»´©ö±N¯f±w¦Ü¤ô¤¤²¾¥X¡C
  2. «O«ù¯f±w¥H­I³¡´Â¤Uªº«º¶Õº}¯B¡C
  3. ºû«ùÀYÀV¡BÂß·F¦¨¤@ª½½u¡C
  4. ºû«ù©I§l¹DºZ³q¡A¥iµ¹¤©©I§l¡C

¡@

·Ä¤ô¯f±w²{³õºò«æ±ÏÅ@¡G1,2,3,7,8

1¡B±µªñ¶Ë±w¡A¥ý½T©w¦Û¨­¦w¥þ¡C

2¡Bª`·N¬O§_¦³¯á´Õ¶Ë®`ªº¥i¯à(¤×¨ä¬O¸õ¤ôªº¯f±w)¡A¤p¤ß¨¾½d¡C

3¡BÂ÷¤ô¤§«e¡A¤@¯ë¤£°µCPR¡A¦ý¥i¦Ò¼{µ¹¤©©I§l¡C

  1. ¦Û¤ô¤¤²¾¥X«á¡AÀ³¾¨¦­¤©¥HCPR(¦pµL©úÅã©I§l¹Dªý¶ë¡A¤@¯ë¤£°µ«¢©i¥ß§J«æ±Ïªk)¡C

5¡Bµ¹¤©100%°ª¿@«×ªº®ñ®ð(Áa¨Ï¯f±w¨S¦³¯gª¬©Î¯gª¬«Ü»´)¡A¨Ã¤©¥H©â§l

  1. ¾¨³t°eÂå¡A(§Y¨Ï¯f±w²{¦b¤w«ì´_¡A¬Ý°_¨Ó«Ü¦n¡A¤]­n°eÂå¡A¦]¦³¥i¯àµo¥Í©µ¿ð©Ê¨Öµo¯g¡A¦p¦¸µo©Ê·Ä¤ô¡^¡C

¡@

¹ï©ó·Ä¤ô¦X¨Ö§CÅé·Åªº¯f±w¡A±`¥Nªí·Ä¤ôªº®É¶¡¸û¤[¡A¹w«á¸û¤£¦n¡C2¦Ó§CÅé·Å¥»¨­¡A§Y¥i¨Ï´åªaªÌ¦Ù¦×¤£ÆF¬¡¡A¦Ó®e©ö·Ä¤ô¡C¦P®É¡A§CÅé·Å¤]®e©ö»¤µo¤ß«ÇÅÖºûŸ°Ê¡A¨ÏªaªÌµo¥Í·Ä¤ô¡C¦]¦¹¡A¤@¯ë«ØÄ³¹ï©ó·Ä¤ô§CÅé·Åªº¯f±w¡A¦b©ñ±ó«æ±Ï«e¡AÀ³¦Ü¤Ö±NÅé·Å¤É¦Ü30-32.5¢J¡A¤×¨ä·í·Ä¤ôªº¬O¤p«Ä¤l®É¡AÀ³±Ï±o§ó¤[¤@ÂI¡C2,3

´¿¦³³ø§iÅã¥Ü¡A¹ï©ó¨ì¹F«æ¶E®É¡Aªì´Áªº®æ©Ô«ä±F©ü°g«ü¼Æ(Glascow coma scale)¬°3¤À¡B»Ý­nCPR¡B«á¨Ó¦í¨ì¥[Å@¯f©Ðªº¤p«Ä¡A¤´¦³24%ªº¯fµ£¡A¤´¥i¥H¯«¸g¾Ç¤W§¹¥þ¥¿±`ªº¥X°|¡A¦]¦¹«æ±ÏªÌ¹ï©ó±Ïªv·Ä¤ôªº¤p«Ä¡AÀ³§ó¿n·¥¨Ç¡C1,9

¡@

·Ä¤ô¯f±w«æ¶Eªº³B¸m­ì«h¡G1,2,3

·Ä¤ô¯f±w¦b«æ¶Eªº³B¸m¥D­n­«ÂI¥]¬Aªì´Áªº´_µd¡BªvÀø©I§l°IºÜ¤Îµû¦ô¦X¨Öªº¶Ë®`¡A¨ä­ì«h¦p¤U:

  1. ¥ýµ¹¯f±w¥Î¤W°ª¿@«×ªº®ñ®ð[¨C¤ÀÄÁ12-15¤½¤Éªº«D¦A©I§l®ñ®ð­±¸n(Non-rebreathing mask)] ¡A¨Ã¨Ï¥Î®ñ®ð¹¡©M«×ºÊµø¾¹(Oximetry)¤Î°Ê¯ß¦å²G®ðÅé¤ÀªR¡A¨Óµû¦ô¯f±w®ñ®ð¤Î®ðÅ饿´«±¡§Î(Áa¨Ï¯f±w¨S¦³¯gª¬©Î¯gª¬«Ü»´·L) ¡C
  2. ¨ú±o¯f¥v¡A¨Ã´M¨D¬O§_¦³¦X¨Ö¨ä¥L¯e¯f©Î¨Öµo¯gªº¥i¯à¡C
  3. °µ¤@¨Ç¥²­nªºÀˬd¡A¦p¯Ý³¡X¥ú¡BC-spine X¥ú(¤×¨ä¯f±w´¿¦³¸õ¤ô) ¡B¦å²G±`³W¡B¾®¦å¥\¯à¡B¹q¸Ñ½è¡BµÇ¥\¯à¡B§¿²G±`³W¡B¦å¤¤°sºë¿@«×©Î¨ä¥¦¬rª«Àˬd¡C
  4. Æ[¹î4-6¤p®É¡A¦p¤´µL¯gª¬¡A¥iÅý¯f±w¥X°|ªð®a°lÂÜ¡C
  5. ¦p¯f±w¦³¥ô¦ó¥Í©RÄp­Ô¡BX¥ú¡B¦å²G®ðÅé¤ÀªR²§±`¡A§¡À³¦í°|ªvÀø¡C
  6. ¦p¯f±w·NÃѲM·¡¡APaO2/FiO2< 300¡A¥i¦Ò¼{µ¹¯f±w¨Ï¥ÎCPAP(contineous positive pressure) ¡C¦p¯f±w®ðºÞµjÅË¡A¦³­ý³Ý­µ¡A¥iµ¹¤©§l¤J£]2(¦pAlbuterol)¥æ·P¯«¸gÃĪ«¡C
  7. ¦p¯f±w·NÃÑ©ü°g©Î¨Ï¥Î«D¦A©I§l®ñ®ð­±¸nPaO2¤´µLªkºû«ù90mmHg¥H¤W¡A©ÎPaCO2µLªkºû«ù45mmHg¥H¤U¡A©ÎPaO2/FiO2< 300®É¡AÀ³¦Ò¼{¤©¥H©ñ¸m®ðºÞ´¡ºÞ¨Ãµ¹¤©¥¿À£©I§l(PEEP, positive end-expiratory pressure) ¡A¥BPEEPÀ³¨Ï¥Î¦Ü¤Ö24¤p®É(¥i«P¶isurfactant¦A¥Í) ¼ç¤ô¬¡°Ê¦P®É¡Aºû«ùPaCO2¦Ü30mmHg¥H§ïµ½¸£¤ô¸~¡C

¡@

»P¼ç¤ô¦³Ãöªº¯e¯f

¥xÆW¥|­±Àô®ü¡A°£¤F­x¨Æ¡Bº®·~¡B°Ó·~¤Î¬ì¾Ç©Ê¼ç¤ô¬¡°Ê¥~¡Aªñ¦~¨Ó®T¼Ö©Ê¼ç¤ô¬¡°Ê³vº¥­·¦æ¡C®Ú¾Ú¬ü°ê²Î­p¡A¬ü°ê±q¨Æ®T¼Ö©Ê¼ç¤ô¬¡°Êªº¤H¤w¶W¹L4¦Ê¸U¤H¡A¨Ã¥H¬ü¦~40¸U¤Hªº³t«×Ä~Äò¦¨ªø¡AÁöµM¼ç¤ô·N¥~ªñ¦~¨Ó¤w¦³´î¤ÖªºÁͶաA¦ý®Ú¾Ú²Î­p1991¦~¥_¬ü¦a°Ï¤´¦³750-800¤Hµo¥ÍÄY­«¼ç¤ô·N¥~¡A¦]¦¹¥¦ªº¦w¥þ¤´­È±o§^¤H­«µø¡C1®Ú¾Ú¥xÆWÀˬÌÁ`©Òªº²Î­p¡A¥Á°ê86¦~¦UÂå°|©Ò³q³øªº¤T¤d¹s¤­­Ó¾·~¬ÛÃö¯e¯f®×¨Ò¤¤¡A´îÀ£¯f§Y¦³¤@¤d¹s¤G¤Q¤G¨Ò¡A¦û©Ò¦³­Ó®×ªº34%¡A±wªÌªº¦æ·~¥Hº®¼´·~³Ì¦h¡A¨ä¦¸¬OÀç³y·~(¥]¬A®ü©³¤uµ{¼ç¤ô¤H­û¡B«õ¤«¤u§@¤H­û¡B¥H¤Î¥H·s¶ø¤uªk¬I¤uªº±¶¹B¤u§@¤H­û)¡B¤Î¥ð¶¢¼ç¤ô¤H­û¡A¥i¨£³oÃþ¯e¯f¦b°ê¤º¤]«D±`¦h¡A¦]¦¹«æ¶E¤u§@¦P¤¯À³¹ï¦¹¯fªp¦³©Ò¤F¸Ñ¡A¥H§K¿ù¥¢¤FªvÀøªº«´¾÷¡CÀHµÛ¥xÆW®ü°ìªº¶}©ñ¡A¯«¯µ¬üÄRªº®ü©³¥@¬É¡A¬Û«H·|§l¤Þ§ó¦h¤H¥[¤J¼ç¤ô¬¡°Ê¡AµM¤ô¤¤Àô¹Òªº§ïÅÜ¡A¹ï¨­Åé©Ò²£¥Íªº¼vÅT¡Aµo¥Íª¬ªp¸Ó¦p¦ó«æ±Ï¡A«o¬O©Ò¦³±q¨Æ¼ç¤ô¬¡°Êªº¤H¤Î«æ±Ï¤H­ûÀ³·í¤F¸Ñªº¡C

¤ô¤¤Àô¹Òªº§ïÅÜ

ÀHµÛ¤ô²`«×ªº¼W¥[¡A¨­Åé©Ò©Ó¨üªºÀ£¤O±N³vº¥¼W¤j¡A¦b®ü¤ô¤¤¤j¬ù¨C¤U­°10¤½¤Ø¡A©Ò©Ó¨üªºÀ£¤O±N¼W¥[1¤j®ðÀ£¡C°£¤FÀ£¤O¼W¥[¥~¡A¤ô¤¤¤]¬O¤@­Ó·Å«×§C¡B¼éÀã¡BÁn¥úª¬ªp§ïÅܤ઱K«×ªºÀô¹Ò¡C·í¼ç¤ôªÌ¤U­°®É¡A¨­Åé©Ò©Ó¨üªºÀ£¤O³vº¥¼W¤j¡AÅ餺®ðÅé¨ü¨ìÀ£ÁY¡F·í¤W¤É®É¡A¨­Åé©Ò©Ó¨üªºÀ£¤O«h³vº¥´î»´¡AÅ餺ªº®ðÅé«h³vº¥¿±µÈ¡A®ðÅé¦bÅé²G¤¤ªº·»¸Ñ«×¤]³vº¥´î§C¡A¤×¨ä¦b±µªñ¤ô­±®É¡AÀ£¤O¤Î®ðªw¤j¤p§ïÅܪº¤ñ¨Ò¬Û¹ï³Ì¦h¡A¦]¦¹¡A¦p¦b±µªñ¤ô­±®É§Ö³t¤W¤É©Î¤U­°¡A±N§ó®e©öµo¥ÍÄY­«ªº¼ç¤ô·N¥~(ªí¤E)¡C10

¡@

ªí¤E ®ü¤ô¤¤À£¤O¤Î®ðªw¤j¤pªº§ïÅÜ

®ü¤ô²`«×(¤½¤Ø)

©Ó¨üªºÀ£¤O(¤j®ðÀ£)

®ðªwªºÅé¿n%

®ðªwªºª½®|%

0

1

100

100

10

2

50

79

20

3

33

69

30

4

25

63

50

6

17

54

¡@

¡@

ªÅ®ð®ê¶ë(air embolism, arterial embolism)

¬O¼ç¤ô¯e¯f¤¤³ÌÄY­«¡A¤]¬O¤@¯ë¼ç¤ô­û³y¦¨¦º¤`¤Î´Ý¯e³Ì¥D­nªº­ì¦]¡C1·í¼ç¤ô¤W¯B®É¡A¥~¬É®ðÀ£«æÁØ­°§C¡A¦¹®ÉªÍ³¡®ðÅ鿱º¦¡A½Ä¯}ªÍªw¡A¦Ó¶i¤JªÍÀR¯ß¡A®ðªw¦^¨ì¤ßŦ«á¡A¸g¥Ñ¥D°Ê¯ß¥iÂà¤J¤ßŦ¡B¸£µ¥³B¡A§Î¦¨ªÅ®ð®ê¶ë¡C¨ä¯gª¬±`µo¥Íªº«D±`¬ðµM¥B«D±`ÄY­«¡A¤@¯ë¦b¤W¯BÂ÷¶}¤ô­±10¤ÀÄÁ¤ºµo¥Í¡A¦Ó¤j¦h¼Æ¯f±w¦b2¤ÀÄÁ¤ºµo¥Í¡CÁöµMªÅ®ð¤]·|¶i¤J«aª¬°Ê¯ß§Î¦¨®ê¶ë©Î¤ßŦ°±¤î¡A¦ý¤j¦h¼Æ±¡ªpªÅ®ð·|¦V¤W¸g¹LÀV°Ê¯ß¦Ó¶i¤J¤j¸£¡A¤@¯ë³Ì±`¼vÅTªº¾¹©xÁÙ¬O¤j¸£¡A¨ä¨å«¬¯gª¬§Y¦p«æ©Ê¤¤­·µo§@¤@¯ë¡A¥]¬A³æªÏ©Î¦hªÏÅ骺ÅõºÈ¡B§½³¡³Â·ô¡B·Pı²§±`¡B¥¢©ú¡BÅ¥¤O³à¥¢¡B¤f¾¦¤£²M¡B¦æ¬°²§±`¡BÀY©ü¡B¹Ã¦R¡BµjÅË¡B©ü°gµ¥¡A¨ä¤¤³Ì±`ªí²{ªº¯gª¬¬O¡A¤£¹ïºÙªº¦hªÏÅõºÈ¡C¤@¯ë¦Ó¨¥¡A¥u­n¬O¯f±w¦b¤ô­±¬ðµo·NÃѳॢ©Î¥ô¦ó¯gª¬¦bÂ÷¶}¤ô­±¤Q¤ÀÄÁ¤ºµo¥ÍªÌ¡A³£À³¥ý°²³]¯f±w¬Oµo¥ÍªÅ®ð®ê¶ë¡A·í°µªÅ®ð®ê¶ë¨ÓªvÀø¡C1,10,11,12

ºò«æ³B²z­ì«h¬°: 1.°ò¥»¥Í©R¤ä«ù¡C

    1. µ¹100%®ñ®ð(¥H«e©Ò¥Îªº¥ª°¼½ö¡BÀY§C¸}°ª«º¶ÕªºªvÀø¤èªk¡A¦]·|¥[­«¸£¤ô¸~¡A¨Ã¨Ï©I§l§ó¬°§xÃø¡A²{¤w¤£«ØÄ³¨Ï¥Î) ¡C
    2. ¥ß§YÂà°e¦Ü¦³°ªÀ£®ñªvÀøªºÂå°|(¦p¥x¥_ºa¥ÁÁ`Âå°|¡B°ò¶©®ü­xÂå°|¡BùªF³Õ·RÂå°|¡B°ª¶¯®ü­xÂå°|)¡CµMªvÀø«eÀ³¥ý±Æ°£®ð¯Ýªº¥i¯à(°ªÀ£®ñªvÀø³q±`·U¦­°µ·U¦n¡AµM¤´¦³¯f±w¦b©µ¿ð¦Ü¤Q¤Ñ«á¤~°µ°ªÀ£®ñ¡A¤´¦³À¸¼@©Ê«ì´_ªº³ø§i) ¡C13±N¯f±w¦AÀ£¤J¤ô¤¤¥[À£¡A³q±`³£·|¨Ï¯fªpÅܱo§óÁV¡A¤£«ØÄ³¨Ï¥Î¡C¥Ñ©ó¤@¯ëª½ª@¾÷¾÷¿µ¤ºµL¥[À£¸Ë¸m¡A¦b°ªªÅ®ðÀ£¸û§C¡A·|¨Ï®ð®ê§ó¬°ÄY­«¡A¦]¦¹¦p¥²¶·­n¨Ï¥ÎªÅ¹B¨ÓÂà°e¯f±w®É¡Aª½ª@¾÷ªº­¸¦æ°ª«×À³§C©ó300¤½¤Ø(¥ç¥i¦Ò¼{¨Ï¥Î¯à±N¾÷¿µ¤º®ðÀ£¡A¥[À£¦Ü1¤j®ðÀ£ªº­¸¾÷)¡C

¡@

¼ç¤ô¤Ò¯f(caisson disease)©Î´îÀ£¯f( decompression sickness)

·í¼ç¤ô¤Ò¤W¤É®É¡A­ì¨Ó·»¸Ñ¦b¦å²G¤¤ªºªº´á®ð¡A¥Ñ©óÀ£¤O­°§C¡AÅé¿n¿±µÈ¡A·|¦b²Õ´©Î¦åºÞ¤¤§Î¦¨¤p®ðªw¡C³q±`¼ç¤ô¤Ò¯f¯f±wªº®ðªw¦h·|¦bÀR¯ß¤¤§Î¦¨(ªÅ®ð®ê¶ë«h¦b°Ê¯ß)¡AªýêÀR¯ß¦^¬y¡AµM®ðªw¥¦¤]¥i¦b²O¤Ú¤º§Î¦¨³y¦¨²O¤Ú¤ô¸~¡A©Î¦b²Ó­M¤º§Î¦¨³y¦¨²Ó­MµÈ¯}ªº²{¶H¡CÀR¯ß¤¤ªº®ðªw¡A¤]¥i¸g¥ÑªÍ¤º©Î¤ß¤º¤À¬y¡A¦Ó³y¦¨°Ê¯ß®ê¶ë¡A®Ú¾Ú³ø§iÅã¥Ü¡A¯«¸g©Ê¼ç¤ô¤Ò¯fªº¯f±w¡A¦X¨Ö°Ê¡BÀR¯ß®ðÅé®ê¶ëªº¤ñ²v¡A´X¥i°ª¹F60-80%¡A¥i¨£°Ê¡BÀR¯ß®ðÅé®ê¶ë¦P®Éµo¥Íªº¤ñ²v«D±`°ª¡C1,10¦¹¥~¡A®ðªw¥»¨­¡A¹ï¨­Åé¦Ó¨¥§Y¬O¤@­Ó¥~ª«¡A¦]¦¹¥i¿E¬¡¾®¦å¦]¤l¡A¦b¦åºÞ¤º§Î¦¨¦å®ê¡A¦Óªýê¦å¬y¡A³y¦¨¦åºÞ¥½ºÝ¯Ê¦å¡CÁöµM¼ç¤ô¤Ò¯f¥i¥X²{¥ô¦óªýê´`Àôªº¯g­Ô¡A¤@¯ë³Ì±`¨£ªºÁÙ¬OÃö¸`¤Î¯áÅ誺¯gª¬¡AÃö¸`¯kµh³Ì±`µo¥Í©óªÓ»H¤Î¤â¨yªºÃö¸`¡A±`¬O²`³¡ªº¶wµh¡AªÏÅ鬡°Ê®É¯kµh·|¥[­«¡A¦p¥Î¦åÀ£­p¦b¯kµhªºÃö¸`¤W¥[À£¡A¯kµh¦h·|´î»´¡C¯áÅ誺¯gª¬¦hµo¥Í©ó¯Ý¡B¸y¤ÎÂË´Õ¡A¦Ó²£¥Í¤UªÏÅõºÈ¤Î§¿²Gº¢¯dªº¯gª¬¡C¨ä¯gª¬¦h¦bÂ÷¶}¤ô­±10¤ÀÄÁ«áµo¥Í(¦p¦b10¤ÀÄÁ¤ºµo¥ÍÀ³¥ý·í°µªÅ®ð®ê¶ë³B²z) ¡A¶W¹L¤@¥bªº¯f±w¯gª¬·|¦b¤@¤p®É¤º¥X²{¡AµM¤´¦³¯f±w¨ìÂ÷¤ô48¤p®É«á¤~¥X²{¯gª¬¡C1,10,12

ºò«æ³B²z­ì«h¥]¬A1.°ò¥»¥Í©R¤ä«ù¡C

    1. µ¹100%®ñ®ð¡C
    2. ¥ß§YÂà°e¦Ü¦³°ªÀ£®ñªvÀøªºÂå°|¡C
    3. ¸É¥R²GÅé(¤fªA©ÎÀR¯ßª`®g) ¡A¤@¯ë¯f±w¦h¦³»´«×¥H¤Wªº²GÅ餣¨¬¡C

¡@

¡@

®ðÀ£³Ð¶Ë(barotrauma)

·íÅ餺ªºªÅ®ðµÄ«Ç(¦p¥~¦Õ¡B¤¤¦Õ¡B¤º¦Õ¡B»óÄu¡B¤ú¼Ñ¡BªÍµ¥¡A©Î¥ô¦ó¥i¯àªºµÄ«Ç¦pÀ¹­±¸n©Ò²£¥ÍªºµÄ«Ç) ¡C¦]»P©P³òÀô¹ÒªºÀ£¤O¤£¬Ûµ¥¡Aµo¥Í¿±µÈ©Î¦¬ÁY¡A¦Ó³y¦¨²Õ´¶Ë®`(¦pÂH½¤¥R¦å¡B¤ô¸~¡B¦åºÞ¯}µõµ¥) ¡A§YºÙ¬°®ðÀ£³Ð¶Ë¡A¥¦¥i©ó¼ç¤ôªÌ¤U­°©Î¤W¤É®Éµo¥Í¡Aµo¥Í²v«D±`°ª¡A´X¥G©Ò¦³ªº¼ç¤ôªÌ¡A³£´¿¸g¾ú¹L»´­«¤£µ¥ªº®ðÀ£³Ð¶Ë¡C¦pÅ餺ªºªÅ®ðµÄ«Ç¡A»P¥~¬Éªº¥æ³qºÞ¹D¦³ªý¶ë®É(¦p¤W©I§l¹D·P¬Vªýê¤F¦Õ«|ºÞ¡B»óÄuªºªÅ®ð¬y³q¡F¦Õ¶ë¡B¦Õ«¯ªýê¤F¦Õ¹DªÅ®ðªº¬y³qµ¥±¡§Î) ¡A«h®ðÀ£³Ð¶Ë§ó®e©öµo¥Í¡C¨ä±`¨£ªº¯g­Ô¥]¬A»´·L©ÎÄY­«ªºÀYµh¡BÀY·w¡B§t¦å©Î¤ôª¬ªº¤Àªcª«¦Û¦Õ©Î»ó¬y¥X¡B¯t·w(¤º¦Õ®ðÀ£³Ð¶Ë±`¥X²{¦Õ»ï¡B¯t·w¤ÎÅ¥¤O³à¥¢ ¡A3­Ó¨å«¬¯g­Ô)²´·ú¥X¦å¡B«y¹Â¡B¯Ýµh¡B«y¦åµ¥¡C1,10,14

ºò«æ³B²z­ì«h¬°: 1.°ò¥»¥Í©R¤ä«ù¡C

    1. µ¹100%®ñ®ðµ¹¤©®ñ®ð(¥²­n®É¤©¥H©â§l) ¡C
    2. µ¹¤©¤ä«ù©ÊªvÀø(¦p¤îµh¾¯¡B§Ü²Õ´»Ï©Î´î»´¥R¦åªºÃĪ«) ¡A¤j¦h¼Æ¯gª¬·|¦ÛµM«ì´_ ¡A¤@¯ë¤£»Ý°ªÀ£¿µªvÀø(°£«D¦X¨ÖªÅ®ð®ê¶ë©Î¼ç¤ô¤Ò¯f ¡A§_«h°ªÀ£¿µªvÀø ¡A¹ï©ó¤º¦Õ®ðÀ£³Ð¶ËªÌ ¡A¬O¬°¸T§Ò) ¡C

¡@

¼ç¤ô¦³Ãö¯e¯fªº¹w¨¾1,10

  1. ®T¼Ö©Ê¼ç¤ôªÌ ¡AÀ³Á×§K¶W¹L100­^§`(33¤½¤Ø)ªº²`¤ô¼ç¤ô¡C
  2. ¤W¤Éªº³t«× ¡AÀ³¤£­n¶W¹L¨C¤ÀÄÁ1­^§`(30¤½¤À) ¡C¤@¯ë¦Ó¨¥¡A¦p¥Ñ30­^§`(9.1¤½¤Ø)ªº²`«×¤W¤É¦Ü¤ô­±¡AÀ³¶W¹L30¤ÀÄÁ¡F¦p¥Ñ60­^§`(18.3¤½¤Ø)ªº²`«×¤W¤É¦Ü¤ô­±¡AÀ³¶W¹L60¤ÀÄÁ ¡C
  3. ¤U­°ªº³t«× ¡AÀ³¤£­n¶W¹L¨C¤ÀÄÁ25­^§`(7.6¤½¤Ø) ¡C
  4. Äá¨ú¨¬°÷ªº¤ô¥÷ ¡A¥Hºû«ù¥¿±`ªº¦å¬yÄéª`¡C
  5. ¼ç¤ô«á12¤p®É¤º(¦³¤H«ØÄ³24¤p®É) ¡AÀ³Á×§K­¼§¤­¸¾÷(¦]¾÷¿µ¤º®ðÀ£¸û§C) ¡C
  6. ¹ï©óªÅ®ð®ê¶ë¡B´îÀ£¯fªº¯f±w¹B°e¡A§CªÅªºª½ª@¾÷¹B°e¡A¦p300¤½¤Ø¥H¤Uªº°ª«×¡A¨Ã¤£»{¬°¬Oµ´¹ï¸T§Ò¡A¦ý°ªªÅªºª½ª@¾÷¹B°e¡A¦p¥Ñ¥xÆWªF³¡¡A­¸¶V¤¤¥¡¤s¯ß¦Ü¦è³¡¡A»Ý­¸¶V¼Æ¤d¤½¤Ø¥H¤Wªº°ª¤s¡A¥Ñ©ó°ªªÅ®ðÀ£§C¡B®ðÅéÅé¿n¿±µÈ©Ò³y¦¨ªº®`³B¡A¤w»·¶W¹Lª½ª@¾÷§Ö³t¹B°eªºÀuÂI¡A¬G¦¹®É¥u¯à¥Ñ³°¸ô¨Ó¹B°e¡A©Î¥Ñª½ª@¾÷ªuµÛ®ü©¤½u§CªÅ¹B°e¦Ü¦è³¡¡A¦Ó¤£¯à­¸¶V¤¤¥¡¤s¯ß¨Ó¹B°e³oÃþ¯f±w¡C
  7. ¦p¦b°ª¤s´òªy¤º¼ç¤ô ¡A¤W¤Éªº³t«×À³§óºC¨Ç¡C
  8. ¼ç¤ô«á6¤p®É¤º ¡AÀ³Á×§K¼@¯P¹B°Ê(¦p½Ä®ö©Î¶]¨B) ¡C

¡@

°Ñ¦Ò¸ê®Æ:

  1. Tintinalli JE, Ruiz E, Krome RL: Dysbarism, Near-drowning :Emergency medicine-A comprehensive study guide 4th ed. 1996; 881-892.
  2. Auerbach PS: Submersion incidents, White- water Medicine and rescue. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed.1995; 1209-1250.
  1. Cummins RO and subcommittee on advanced cardiac life support, American Heart Association: Special resuscitation Situations. Textbook of Advanced Cardiac Life Support. 1997; 11-1¡X11-19.
  2. Macnab AJ: Effective interventions for nearly drowned children. Canadian Family Physician. 1995; 41:1545-8, 1551-2, 1555-6.
  3. Modell JH, Davis JH. Is Heimlich maneuver appropriate as first treatment for drowing? Emerg Med Serv. 1981; 10: 63-66.
  4. Heimlich HJ. The Heimlich maneuver: The first treatment for drowing victims. Emerg Med Serv. 1981; 10:58-61.
  5. Stoy WA and the center for emergency Environmental emergencies. Mosby¡¦s EMT-basic textbook. 1996. 314-27.
  6. ­J³Ó¤t¡B°ª°¶®p¡B½²­õ§»µ¥. Àô¹Ò«æ¯g.¹ê¥Î¨ì°|«eºò«æÂåÀø±ÏÅ@, 1996, 13-27.
  7. Quan L, Kinder D: Pediatric submersions: prehospital predictors of outcome, Pediatrics 1992; 90(6): 909.
  8. Auerbach PS:Scuba diving and dysbarism. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed.1995; 1176-1208.
  9. Kizer KW: Delayed treatment of dysbarism; a retrospective review of 50 cases. JAMA 247:2555, 1982.
  10. Kizer KW: Dysbaric cerebral air embolism in Hawaii. Ann Emerg Med 16:535, 1987.
  11. Tabrah FL.Tanner R.Vega R: Baromedicine today-rational uses of hyperbarbic oxygen therapy. Hawaii Medical Journal. 1994; 53(4):112-5.

14. Rawlings JSP: Physical and pathophysiological effects of blast. Injury 9:313, 1977.

¡@